EP0625200B1
(de)
|
1992-02-06 |
2005-05-11 |
Chiron Corporation |
Marker für krebs und biosynthetisches bindeprotein dafür
|
US6329507B1
(en)
*
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
DE69334287D1
(de)
*
|
1992-09-25 |
2009-07-09 |
Avipep Pty Ltd |
Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
|
ATE367827T1
(de)
|
1992-11-16 |
2007-08-15 |
Centocor Inc |
Verfahren zur reduzierung der immunogenizität der variablen regionen von antikörpern
|
AU5670194A
(en)
*
|
1992-11-20 |
1994-06-22 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
WO1994013804A1
(en)
*
|
1992-12-04 |
1994-06-23 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
CA2117477C
(en)
*
|
1992-12-11 |
2001-06-12 |
Peter S. Mezes |
Multivalent single chain antibodies
|
GB9412166D0
(en)
*
|
1993-09-22 |
1994-08-10 |
Medical Res Council |
Retargetting antibodies
|
JPH09503759A
(ja)
|
1993-09-22 |
1997-04-15 |
メディカル リサーチ カウンシル |
抗体のリターゲッティング
|
WO1995009917A1
(en)
*
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
US5837544A
(en)
*
|
1995-02-02 |
1998-11-17 |
Cell Genesys, Inc. |
Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US5641870A
(en)
*
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
AU6873396A
(en)
*
|
1995-10-16 |
1997-05-07 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
ES2225961T3
(es)
|
1996-04-04 |
2005-03-16 |
Unilever N.V. |
Proteina de union a antigeno multivalente y multiespecifica.
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
IT1286663B1
(it)
*
|
1996-06-27 |
1998-07-15 |
Ministero Uni Ricerca Scient E |
Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
|
GB9712818D0
(en)
*
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
PT973804E
(pt)
|
1997-04-07 |
2007-03-30 |
Genentech Inc |
Anticorpos anti-vegf
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
CA2288994C
(en)
|
1997-04-30 |
2011-07-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
GB9710154D0
(en)
*
|
1997-05-16 |
1997-07-09 |
Medical Res Council |
Detection of retroviruses
|
CA2289665C
(en)
|
1997-06-13 |
2005-08-09 |
Genentech, Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
*
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
DK1027439T3
(da)
|
1997-10-27 |
2010-05-10 |
Bac Ip Bv |
Multivalente antigenbindende proteiner
|
EP2014677A1
(de)
|
1997-11-21 |
2009-01-14 |
Genentech, Inc. |
Mit A33 vewandte Antigene und deren pharmazeutische Verwendung
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
EP1947119A3
(de)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
|
ATE393912T1
(de)
|
1998-02-04 |
2008-05-15 |
Invitrogen Corp |
Microarrays und ihre verwendungen
|
EP2050762A3
(de)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Neue Polypeptide und für diese kodierende Nukleinsäuren
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
HUP9900956A2
(hu)
*
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
CA2328496C
(en)
|
1998-05-15 |
2016-01-05 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
CA2381495A1
(en)
*
|
1999-08-11 |
2001-02-22 |
Unilever Plc |
Internally referenced immunoassay and test device
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
BR0015055A
(pt)
|
1999-10-20 |
2002-07-16 |
Genentech Inc |
Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
|
EP1250426A2
(de)
|
1999-12-01 |
2002-10-23 |
Genentech Inc. |
Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäuren
|
EP1897945B1
(de)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
NZ520095A
(en)
|
2000-01-13 |
2004-05-28 |
Genentech Inc |
Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth
|
WO2001062800A1
(en)
|
2000-02-24 |
2001-08-30 |
Eidgenössische Technische Hochschule Zürich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
SI2857516T1
(sl)
|
2000-04-11 |
2017-09-29 |
Genentech, Inc. |
Multivalentna protitelesa in njihove uporabe
|
DE10021678A1
(de)
*
|
2000-05-05 |
2002-04-18 |
Stefan Duebel |
Antikörperkonstrukte mit variablen Regionen
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
EP2075253A1
(de)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
|
EP2792747A1
(de)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
WO2002085405A2
(en)
|
2001-04-24 |
2002-10-31 |
Merck Patent Gmbh |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ATE446317T1
(de)
|
2001-05-11 |
2009-11-15 |
Ludwig Inst For Cancer Res Ltd |
Spezifische bindungsproteine und ihre verwendung
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
NZ529612A
(en)
|
2001-05-30 |
2006-03-31 |
Genentech Inc |
Anti-NGF antibodies for the treatment of various disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100576674B1
(ko)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20030148408A1
(en)
|
2001-09-18 |
2003-08-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
NZ530852A
(en)
|
2001-08-27 |
2006-11-30 |
Genentech Inc |
Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
|
JP4361791B2
(ja)
|
2001-08-29 |
2009-11-11 |
ジェネンテック・インコーポレーテッド |
マイトジェン活性を有するBv8核酸及びポリペプチド
|
EP1439857B1
(de)
|
2001-10-12 |
2009-02-25 |
Schering Corporation |
VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2005535282A
(ja)
*
|
2001-11-16 |
2005-11-24 |
アイデック ファーマシューティカルズ コーポレイション |
抗体のポリシストロニック発現
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
KR100801388B1
(ko)
|
2002-01-02 |
2008-02-05 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US20050158296A1
(en)
|
2002-01-11 |
2005-07-21 |
Starr Christopher M. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
EP2388265A1
(de)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
EP2277522B1
(de)
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen
|
US7166425B2
(en)
|
2002-04-12 |
2007-01-23 |
Colorado School Of Mines |
Method for detecting low concentrations of a target bacterium that uses phages to infect target bacterial cells
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
EP1513879B1
(de)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Bibliotheken synthetischer antikörperphagen
|
US7585501B2
(en)
|
2002-06-14 |
2009-09-08 |
Stowers Institute For Medical Research |
Compositions and methods for treating kidney disease
|
EP1572130A4
(de)
|
2002-07-08 |
2008-07-02 |
Genentech Inc |
Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
|
PT2263691E
(pt)
|
2002-07-15 |
2012-11-12 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
|
EP2281578A3
(de)
|
2002-07-15 |
2011-04-13 |
Board of Regents, The University of Texas System |
Ausgewählte Antikörper und Duramycin-Peptide mit Bindung an anionische Phospholipide und Aminophospholipide und ihre Verwendung bei der Behandlung von Virusinfektionen und Krebs
|
AU2003251238A1
(en)
|
2002-08-07 |
2004-02-25 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
US20060199181A1
(en)
|
2002-09-11 |
2006-09-07 |
Genentch, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP3388452A3
(de)
|
2002-09-11 |
2019-02-20 |
Genentech, Inc. |
Proteinreinigung
|
DE60335552D1
(de)
|
2002-09-11 |
2011-02-10 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
EP1578364A4
(de)
|
2002-09-16 |
2011-06-08 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
|
EP1585482A4
(de)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
Neue zusammensetzungen und verfahren zur behandlung von psoriasis
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
SG146441A1
(en)
|
2002-10-22 |
2008-10-30 |
Eisai R&D Man Co Ltd |
Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
|
EP2322203A3
(de)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
|
EP1581169A4
(de)
|
2002-11-08 |
2008-09-17 |
Genentech Inc |
Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen
|
ITMI20022411A1
(it)
*
|
2002-11-14 |
2004-05-15 |
Bracco Imaging Spa |
Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
|
ATE466885T1
(de)
|
2002-11-15 |
2010-05-15 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
EP1572976B1
(de)
|
2002-11-21 |
2010-09-15 |
Celltech R & D, Inc. |
Modulieren von immunantworten
|
CA2504144A1
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
EP2390270A1
(de)
|
2003-01-10 |
2011-11-30 |
Ablynx N.V. |
Therapeutische Polypeptide, Homologe davon, Fragmente davon und Verwendung bei modulierender plättchenvermittelter Aggregation
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
MXPA05007843A
(es)
|
2003-01-24 |
2005-10-18 |
Elan Pharm Inc |
Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
|
EP1594956A4
(de)
|
2003-02-03 |
2007-08-01 |
Fraunhofer Usa Inc |
System zur expression von genen in pflanzen
|
EP2526960A1
(de)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Verwendung von BV8 und/oder EG-VEGF zum Fördern der Hämatopoiese
|
PL2335725T3
(pl)
|
2003-04-04 |
2017-04-28 |
Genentech, Inc. |
Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
EP1626993B1
(de)
|
2003-05-09 |
2015-03-11 |
Duke University |
Cd20-spezifische antikörper und verfahren zur anwendung derselben
|
EP1664322B1
(de)
|
2003-05-22 |
2013-07-10 |
Fraunhofer USA, Inc. |
Rekombinantes trägermolekül zur expression, zuführung und reinigung von zielpolypeptiden
|
WO2004111192A2
(en)
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
KR20170073698A
(ko)
|
2003-05-30 |
2017-06-28 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
ES2348008T3
(es)
|
2003-06-18 |
2010-11-26 |
Chugai Seiyaku Kabushiki Kaisha |
Transportador de fucosa.
|
PL1641822T3
(pl)
|
2003-07-08 |
2013-10-31 |
Genentech Inc |
Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
|
DE10331054A1
(de)
*
|
2003-07-09 |
2005-02-03 |
Schering Ag |
Emitter-bindende Peptide die eine Veränderung der spektralen Emissionseigenschaften des Emitters bewirken
|
WO2005005482A1
(de)
*
|
2003-07-09 |
2005-01-20 |
Schering Ag |
Emitter-bindende peptide die eine veränderung der spektralen emissionseigenschaften des emitters bewirken
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US7304139B2
(en)
|
2003-10-28 |
2007-12-04 |
University Of Florida Research Foundation, Inc. |
Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
|
CN1878568A
(zh)
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
PE20090047A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
ES2382942T3
(es)
|
2003-11-13 |
2012-06-14 |
Sutter West Bay Hospitals |
Terapia anti-pecam para la supresión de la metástasis
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
JPWO2005056605A1
(ja)
|
2003-12-12 |
2007-12-06 |
中外製薬株式会社 |
3量体以上の受容体を認識する改変抗体
|
HUE039803T2
(hu)
|
2004-01-07 |
2019-02-28 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specifikus monoklonális ellenanyag és alkalmazásai
|
EP3653641A1
(de)
|
2004-02-19 |
2020-05-20 |
Genentech, Inc. |
Antikörper mit korrigiertem cdr
|
KR100923828B1
(ko)
|
2004-03-31 |
2009-10-27 |
캐논 가부시끼가이샤 |
금-결합성 단백질
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
JP2007538258A
(ja)
|
2004-05-15 |
2007-12-27 |
ジェネンテック・インコーポレーテッド |
標的分子に結合親和性を有する分子を検出するためのクロススクリーニングシステムと方法
|
NZ551627A
(en)
|
2004-05-28 |
2010-02-26 |
Agensys Inc |
Antibodies and related molecules that bind to PSCA proteins
|
CN106075435A
(zh)
|
2004-06-04 |
2016-11-09 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
US7604947B2
(en)
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
WO2006012361A2
(en)
|
2004-07-01 |
2006-02-02 |
University Of Southern California |
Genetic markers for predicting disease and treatment outcome
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
KR20180091967A
(ko)
|
2004-07-22 |
2018-08-16 |
제넨테크, 인크. |
Her2 항체 조성물
|
CN101027390B
(zh)
|
2004-07-22 |
2012-12-12 |
卫材R&D管理有限公司 |
Lrp4/Corin多巴胺能神经元祖细胞标志物
|
EP1774017B1
(de)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Verfahren zur verbesserten proteinexpression durch strain-engineering
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
EP1778871B1
(de)
|
2004-08-06 |
2011-05-04 |
Genentech, Inc. |
Tests und verfahren unter verwendung von biomarkern
|
WO2006017859A2
(en)
|
2004-08-06 |
2006-02-16 |
Genentech, Inc. |
Assays and methods using biomarkers
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
US20060110387A1
(en)
|
2004-10-05 |
2006-05-25 |
Genentech, Inc. |
Method for treating vasculitis
|
CN101080487B
(zh)
|
2004-10-07 |
2012-11-14 |
阿戈斯治疗公司 |
成熟树突细胞组合物及其培养方法
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
CA2584305A1
(en)
|
2004-10-21 |
2006-05-04 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
CN101098889A
(zh)
|
2004-11-05 |
2008-01-02 |
盘林京有限公司 |
抗体导致的细胞膜损伤
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
EP2208783A1
(de)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur Herstellung eines Antikörpers unter Verwendung einer Zelle mit gehemmter Fucosetransporterfunktion
|
JP2008525002A
(ja)
|
2004-12-23 |
2008-07-17 |
ラボラトワール セローノ ソシエテ アノニム |
Bcmaポリペプチド及びその使用
|
EP1841793B1
(de)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
DE602006015281D1
(de)
|
2005-01-14 |
2010-08-19 |
Ablynx Nv |
Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
|
KR20170134771A
(ko)
|
2005-01-21 |
2017-12-06 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
KR101253576B1
(ko)
|
2005-02-23 |
2013-04-11 |
제넨테크, 인크. |
Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
US8092990B2
(en)
|
2005-03-31 |
2012-01-10 |
Colorado School Of Mines |
Apparatus and method for detecting microscopic organisms using bacteriophage
|
EP3300739A3
(de)
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
|
PL1876236T3
(pl)
|
2005-04-08 |
2015-01-30 |
Chugai Pharmaceutical Co Ltd |
Przeciwciała zastępujące czynność czynnika krzepnięcia VIII
|
US7939642B2
(en)
|
2005-04-09 |
2011-05-10 |
Fusion Antibodies Limited |
Antibody and uses thereof
|
CA2605507C
(en)
|
2005-04-19 |
2016-06-28 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
EP1885755A4
(de)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
Cd19-antikörper-therapie für autoimmunerkrankungen
|
AU2007254715B2
(en)
|
2005-05-06 |
2013-08-29 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
|
SI1879573T1
(sl)
|
2005-05-10 |
2013-04-30 |
Incyte Corporation Experimental Station |
Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
|
US8329652B2
(en)
|
2005-05-10 |
2012-12-11 |
Neoloch Aps |
Neuritogenic peptides
|
MX2007014564A
(es)
|
2005-05-20 |
2008-02-07 |
Ablynx Nv |
Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
PT2163562E
(pt)
|
2005-06-21 |
2013-12-19 |
Xoma Us Llc |
Anticorpos de ligação a il 1 beta e respectivos fragmentos
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
EP4026840A1
(de)
|
2005-07-18 |
2022-07-13 |
Seagen Inc. |
Beta-glukuronid-linker-wirkstoffkonjugate
|
NI200800032A
(es)
*
|
2005-07-25 |
2009-03-23 |
|
Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
|
US8652469B2
(en)
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
ES2702650T3
(es)
|
2005-07-29 |
2019-03-04 |
The Government Of The Us Secretary Of Health And Human Services |
Exotoxinas de pseudomonas mutadas con antigenicidad reducida
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
AU2006341615A1
(en)
|
2005-08-03 |
2007-10-18 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
DE602006019262D1
(de)
|
2005-08-11 |
2011-02-10 |
Siemens Healthcare Diagnostics |
QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
ES2376479T3
(es)
|
2005-08-16 |
2012-03-14 |
Genentech, Inc. |
Sensibilidad apoptótica a apo2l/trail mediante el ensayo de expresión de galnac-t14 en células y tejidos.
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
SG10201402712QA
(en)
|
2005-08-31 |
2014-08-28 |
Merck Sharp & Dohme |
Engineered anti-il-23 antibodies
|
WO2007027761A2
(en)
|
2005-09-01 |
2007-03-08 |
Schering Corporation |
Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
|
EP1945240B1
(de)
|
2005-09-16 |
2016-12-28 |
Raptor Pharmaceutical Inc |
Zusammensetzungen mit rezeptor-assoziierten protein (rap) varianten, die für cr-haltige proteine spezifisch sind und ihre verwendungen
|
EP3299027A1
(de)
|
2005-11-04 |
2018-03-28 |
Genentech, Inc. |
Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
NZ568324A
(en)
|
2005-11-11 |
2012-01-12 |
Vertex Pharma |
Hepatitis C virus variants
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
JP5184367B2
(ja)
|
2005-11-18 |
2013-04-17 |
グレンマーク・ファーマシューティカルズ・エスエー |
抗アルファ2インテグリン抗体およびその使用
|
WO2007081608A2
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
EP2567973B1
(de)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21-Antagonisten
|
ES2388932T3
(es)
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
US20090246208A1
(en)
|
2006-01-05 |
2009-10-01 |
Novartis Ag |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
AU2007215080A1
(en)
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Influenza antigens, vaccine compositions, and related methods
|
EP2412727B1
(de)
|
2006-02-14 |
2016-06-29 |
University Of Tasmania Through The Menzies Research Institute |
Von Metallothionein abgeleitete Peptidfragmente
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
WO2007100711A2
(en)
|
2006-02-24 |
2007-09-07 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
EP2540741A1
(de)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
JP2009534297A
(ja)
|
2006-03-10 |
2009-09-24 |
ザイモジェネティクス, インコーポレイテッド |
Il−17aおよびil−17fの両方に結合する抗体ならびにその使用方法
|
DK2359834T5
(en)
|
2006-03-15 |
2017-02-06 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
BRPI0709598A8
(pt)
|
2006-03-17 |
2019-01-08 |
Biogen Idec Inc |
composições de polipeptídeos estabilizados
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
ES2544957T3
(es)
|
2006-03-21 |
2015-09-07 |
Genentech, Inc. |
Terapia combinada que implica antagonistas alfa5beta1
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
AU2007246921A1
(en)
|
2006-04-10 |
2007-11-15 |
Fusion Antibodies Limited |
Therapy targeting Cathepsin S
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
AU2007247137A1
(en)
|
2006-05-02 |
2007-11-15 |
Actogenix N.V. |
Microbial intestinal delivery of obesity related peptides
|
AU2007249160B2
(en)
|
2006-05-15 |
2013-09-12 |
I2 Pharmaceuticals, Inc. |
Neutralizing antibodies to influenza viruses
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US20080138334A1
(en)
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
US8796429B2
(en)
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
SG175615A1
(en)
|
2006-06-06 |
2011-11-28 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
MX2008015524A
(es)
*
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
RU2009100930A
(ru)
|
2006-06-14 |
2010-07-20 |
Чугаи Сейяку Кабусики Кайся (Jp) |
Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
US20130004480A1
(en)
|
2006-07-04 |
2013-01-03 |
Paul Parren |
CD20 Binding Molecules for the Treatment of Copd
|
PE20081004A1
(es)
|
2006-07-13 |
2008-09-18 |
Chugai Pharmaceutical Co Ltd |
Agentes inductores de muerte celular
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
CA2658612C
(en)
|
2006-08-03 |
2015-11-17 |
Astrazeneca Ab |
Antibodies directed to .alpha.v.beta.6 and uses thereof
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
JP5317697B2
(ja)
|
2006-08-14 |
2013-10-16 |
中外製薬株式会社 |
抗Desmoglein3抗体を用いる癌の診断および治療
|
ES2444065T3
(es)
|
2006-08-18 |
2014-02-24 |
Novartis Ag |
Anticuerpo específico para PRLR y usos del mismo
|
JP4780405B2
(ja)
*
|
2006-08-29 |
2011-09-28 |
アイシン精機株式会社 |
結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
EP3199549A1
(de)
|
2006-09-05 |
2017-08-02 |
Alexion Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung antikörper-vermittelter nervenleiden
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
AU2007312367B2
(en)
|
2006-10-12 |
2012-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-EREG antibody
|
US20100061933A1
(en)
|
2006-10-20 |
2010-03-11 |
Naoki Kimura |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
JP5676849B2
(ja)
|
2006-10-20 |
2015-02-25 |
中外製薬株式会社 |
抗hb−egf抗体を有効成分として含む癌治療剤
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
US7829674B2
(en)
|
2006-10-27 |
2010-11-09 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
CN101687031B
(zh)
|
2006-10-27 |
2014-05-14 |
勒帕斯公司 |
用于治疗眼疾和眼病的组合物及方法
|
JP2010509244A
(ja)
|
2006-11-13 |
2010-03-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
癌性疾患修飾抗体
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
EP2962697A1
(de)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
CN101687032A
(zh)
|
2006-12-07 |
2010-03-31 |
诺瓦提斯公司 |
抗ephb3的拮抗剂抗体
|
AU2007332473B2
(en)
|
2006-12-14 |
2012-09-27 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
CN101605814B
(zh)
|
2006-12-14 |
2014-02-19 |
默沙东公司 |
经工程改造的抗tslp抗体
|
KR20150097813A
(ko)
|
2006-12-19 |
2015-08-26 |
제넨테크, 인크. |
조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
|
EP2094306A2
(de)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Behandlung von il-1-beta-bedingten erkrankungen
|
WO2008143713A2
(en)
|
2006-12-22 |
2008-11-27 |
Dow Agrosciences Llc |
Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences
|
EP2123676A4
(de)
|
2007-01-05 |
2011-01-05 |
Univ Tokyo |
Diagnose und behandlung von krebs unter verwendung von anti-prg-3-antikörpern
|
WO2008084402A2
(en)
|
2007-01-11 |
2008-07-17 |
Philipps-Universitaet Marburg |
Diagnosis and treatment of alzheimer's and other neurodementing diseases
|
WO2008092041A2
(en)
|
2007-01-24 |
2008-07-31 |
Carnegie Mellon University |
Optical biosensors
|
JP5276017B2
(ja)
|
2007-01-25 |
2013-08-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Egfr変異体仲介性疾患の治療における抗egfr抗体の使用
|
WO2008096817A1
(ja)
|
2007-02-09 |
2008-08-14 |
Eisai R & D Management Co., Ltd. |
Gabaニューロン前駆細胞マーカー65b13
|
US20090075378A1
(en)
|
2007-02-20 |
2009-03-19 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
CA2678863A1
(en)
|
2007-02-23 |
2008-08-28 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
PL2059534T3
(pl)
|
2007-02-23 |
2012-09-28 |
Merck Sharp & Dohme |
Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
|
WO2008103702A2
(en)
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
CA2679266A1
(en)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
|
KR20100014568A
(ko)
|
2007-02-28 |
2010-02-10 |
쉐링 코포레이션 |
가공된 항-il-23r 항체
|
NZ597915A
(en)
|
2007-02-28 |
2013-08-30 |
Merck Sharp & Dohme |
Combination therapy for treatment of immune disorders
|
EP2899541A1
(de)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
EP1975184A3
(de)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serin- oder Threonin-Phosphorylationsorte
|
US7928202B2
(en)
|
2007-04-12 |
2011-04-19 |
The Brigham And Women's Hospital, Inc. |
Targeting ABCB5 for cancer therapy
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
EP2145902A3
(de)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
WO2008134659A2
(en)
|
2007-04-27 |
2008-11-06 |
Zymogenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
WO2008134461A2
(en)
|
2007-04-27 |
2008-11-06 |
Dow Global Technologies, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
WO2008134643A2
(en)
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
JP5989299B2
(ja)
|
2007-05-30 |
2016-09-07 |
エルパス・インコーポレイテッドLpath, Inc. |
リゾホスファチジン酸結合のための組成物と方法
|
RU2473563C2
(ru)
|
2007-06-07 |
2013-01-27 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
SI2170956T1
(sl)
|
2007-06-15 |
2015-02-27 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Zdravljenje tumorjev z uporabo specifičnega protitelesa proti L1
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
BRPI0814060A2
(pt)
*
|
2007-07-06 |
2015-01-06 |
Trubion Pharmaceuticals Inc |
Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
RS52305B
(en)
|
2007-07-16 |
2012-12-31 |
Genentech Inc. |
ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
WO2009023185A1
(en)
|
2007-08-13 |
2009-02-19 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
US8916135B2
(en)
|
2007-08-22 |
2014-12-23 |
Colorado School Of Mines |
Lanthanide nanoparticle conjugates and uses thereof
|
AU2008296194B2
(en)
|
2007-09-04 |
2013-03-14 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity
|
EP3753947A1
(de)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
|
US7704508B2
(en)
|
2007-09-14 |
2010-04-27 |
New York Blood Center |
Babesia subtilisin
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP2348052A3
(de)
|
2007-09-17 |
2011-10-26 |
The Regents of The University of California |
Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
|
EP2195341B1
(de)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Fusionsantikörper mit dualer spezifität
|
SI2202245T1
(sl)
|
2007-09-26 |
2016-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
|
GB0718843D0
(en)
|
2007-09-26 |
2007-11-07 |
Cancer Rec Tech Ltd |
Materials and methods relating to modifying the binding of antibodies
|
CA2701032C
(en)
|
2007-09-27 |
2021-01-26 |
Amgen Inc. |
Pharmaceutical formulations
|
US8268783B2
(en)
|
2007-09-28 |
2012-09-18 |
Portola Pharmaceuticals, Inc. |
Antidotes for factor Xa inhibitors and methods of using the same
|
CA2697583C
(en)
|
2007-09-28 |
2016-04-12 |
Portola Pharmaceuticals, Inc. |
Antidotes for factor xa inhibitors and methods of using the same
|
US20110014196A1
(en)
*
|
2007-10-03 |
2011-01-20 |
Covalys Biosciences Ag |
Drug Transfer into Living Cells
|
WO2009046388A1
(en)
|
2007-10-03 |
2009-04-09 |
United States Medical Research & Material Command |
Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
CA2702637A1
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
DK2215117T4
(en)
|
2007-10-30 |
2018-04-09 |
Genentech Inc |
ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
|
US8158762B2
(en)
|
2007-11-08 |
2012-04-17 |
Genentech, Inc. |
Anti-factor B antibodies and their uses
|
EA034136B1
(ru)
|
2007-11-09 |
2020-01-09 |
Перигрин Фармасьютикалз, Инк. |
Изолированное антитело, которое связывается с vegf, и его применения
|
PT2220116E
(pt)
|
2007-11-12 |
2012-12-07 |
Theraclone Sciences Inc |
Composições e métodos para a terapia e o diagnóstico da gripe
|
AU2008321840B2
(en)
|
2007-11-14 |
2014-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
RU2559530C2
(ru)
|
2007-11-15 |
2015-08-10 |
Чугаи Сейяку Кабусики Кайся |
Моноклональные антитела, способные связываться с белком axl, и их применение
|
EP3115469B1
(de)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lungenkrebsmarker und verwendungen davon
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
AU2008334095A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
GB0723797D0
(en)
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
DK2236604T3
(en)
|
2007-12-05 |
2016-10-03 |
Chugai Pharmaceutical Co Ltd |
The anti-NR10 antibody and use thereof
|
EP2067787A1
(de)
|
2007-12-06 |
2009-06-10 |
Boehringer Ingelheim International GmbH |
Verfahren zur Kontrolle von Insektenpopulationen
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
CA2709354C
(en)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
US8697434B2
(en)
|
2008-01-11 |
2014-04-15 |
Colorado School Of Mines |
Detection of phage amplification by SERS nanoparticles
|
US9274119B2
(en)
|
2008-01-11 |
2016-03-01 |
The University Of Tokyo |
Anti-CLDN6 antibody
|
EP2085095B1
(de)
|
2008-01-17 |
2012-03-07 |
Philogen S.p.A. |
Kombination aus einem Anti-EDb-Fibronectin-Antikörper-IL-2-Fusionsprotein und einem B-Zellen bindenden Molekül, B-Zellen-Vorläufern und/oder deren krebserregendem Gegenspieler
|
EP2574628B1
(de)
|
2008-01-25 |
2015-05-20 |
Amgen Inc. |
Ferroportin-Antikörper und Verwendungsverfahren
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
AU2009223688B2
(en)
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
US8609105B2
(en)
|
2008-03-18 |
2013-12-17 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
EP2274008B1
(de)
|
2008-03-27 |
2014-02-26 |
ZymoGenetics, Inc. |
Zusammensetzungen und verfahren zur hemmung von pdgfrbeta und vegf-a
|
CN102046656A
(zh)
|
2008-03-28 |
2011-05-04 |
航道生物技术有限责任公司 |
针对病毒抗原的中和性分子
|
US9441204B2
(en)
|
2008-04-03 |
2016-09-13 |
Colorado School Of Mines |
Compositions and methods for detecting Yersinia pestis bacteria
|
WO2009124294A2
(en)
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
KR101855381B1
(ko)
|
2008-04-09 |
2018-05-09 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
WO2009126306A2
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
SI2132228T1
(sl)
*
|
2008-04-11 |
2011-10-28 |
Emergent Product Dev Seatle |
CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2009139822A1
(en)
|
2008-05-01 |
2009-11-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
EP2116555A1
(de)
|
2008-05-08 |
2009-11-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom
|
US8680025B2
(en)
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Microarray system
|
US8680026B2
(en)
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Flow cell device
|
JP5490783B2
(ja)
|
2008-05-09 |
2014-05-14 |
アコーニ バイオシステムズ |
マイクロアレイシステム
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2291399B1
(de)
|
2008-05-22 |
2014-06-25 |
Bristol-Myers Squibb Company |
Polyvalente proteine mit fibronectin-gerüstdomänen
|
EP3002299A1
(de)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
CA2728473A1
(en)
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
EP2732823B1
(de)
|
2008-06-25 |
2019-08-07 |
H. Lundbeck A/S |
Modulation des TrpV: Vps10p-Domänen-Rezeptorsystem zur Behandlung von Schmerzen
|
NO2824100T3
(de)
|
2008-07-08 |
2018-07-21 |
|
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
US8993728B2
(en)
|
2008-07-16 |
2015-03-31 |
Medical And Biological Laboratories Co., Ltd. |
Anti-human CLCP1 antibody and use thereof
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
CA2737146A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
MX2011001506A
(es)
|
2008-08-14 |
2011-03-15 |
Genentech Inc |
Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
|
US8968705B2
(en)
|
2008-08-22 |
2015-03-03 |
Colorado School Of Mines |
Gold/lanthanide nanoparticle conjugates and uses thereof
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
US8193321B2
(en)
|
2008-09-03 |
2012-06-05 |
Genentech, Inc. |
Multispecific antibodies
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
EP2927244A1
(de)
|
2008-09-19 |
2015-10-07 |
MedImmune, LLC |
Gegen DLL4 gerichtete Antikörper und ihre Verwendung
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
BRPI0920453A2
(pt)
|
2008-10-09 |
2015-12-22 |
Tufts College |
pelicula de seda, construção para engenharia de tecido, metodos para preparar uma película de seda, para cobrir uma superfície de um substrato com uma composição de seda, e para embutir pelo menos um agente ativo em uma película de seda, e, substrato coberto com película de sedal
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
NZ592436A
(en)
|
2008-11-06 |
2012-10-26 |
Glenmark Pharmaceuticals Sa |
Treatment with anti-alpha2 integrin antibodies
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
ES2719496T3
(es)
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
US8329188B2
(en)
|
2008-11-12 |
2012-12-11 |
Theraclone Sciences, Inc. |
Human M2e peptide immunogens
|
CN102215869B
(zh)
|
2008-11-13 |
2015-05-13 |
通用医疗公司 |
用于通过调整bmp-6来调节铁稳态的方法和组合物
|
BRPI0921586A2
(pt)
|
2008-11-18 |
2019-09-24 |
Merrimack Pharmaceuticals Inc |
articuladores de albumina de soro humana e conjugados destes
|
ATE523603T1
(de)
|
2008-11-21 |
2011-09-15 |
Chimera Biotec Gmbh |
Konjugatkomplexe zum analytnachweis
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
JP5761653B2
(ja)
|
2008-12-04 |
2015-08-12 |
ランケナー インスティテュート フォー メディカル リサーチ |
水晶体線維症疾患の治療および予防用の組成物と方法
|
UA109108C2
(uk)
|
2008-12-09 |
2015-07-27 |
Дженентек, Інк. |
Антитіло до pd-l1 та його застосування для посилення функції t-клітин
|
EP2376117A1
(de)
|
2008-12-17 |
2011-10-19 |
Genentech, Inc. |
Hepatitis-c-virus-kombinationstherapie
|
EP2379710A1
(de)
|
2008-12-19 |
2011-10-26 |
Schering Corporation |
Futterzusatz für die säugerzellkultur und verwendungsverfahren
|
US8846870B2
(en)
|
2008-12-22 |
2014-09-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-HS6ST2 antibodies and uses thereof
|
EP2377921B1
(de)
|
2008-12-22 |
2016-04-13 |
Eisai R&D Management Co., Ltd. |
Verfahren zur gewinnung von pankreasvorläuferzellen mittels neph3
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
EP2385114A4
(de)
|
2008-12-25 |
2012-08-08 |
Univ Tokyo |
Krebsbehandlungsdiagnose mit anti-tm4sf20-antikörper
|
WO2010074192A1
(ja)
|
2008-12-26 |
2010-07-01 |
国立大学法人東京大学 |
抗lgr7抗体を用いる癌の診断および治療
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
EP2403528B1
(de)
|
2009-03-02 |
2016-04-20 |
Aduro Biotech Holdings, Europe B.V. |
Antikörper gegen einen proliferations-induzierenden liganden (april)
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2230515B1
(de)
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivierung von Oberflächen nach Ligandenkupplung
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
MX347295B
(es)
|
2009-03-20 |
2017-04-20 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
JP6051048B2
(ja)
|
2009-03-25 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
新規な抗α5β1抗体及びその使用
|
HUE025726T2
(en)
|
2009-03-25 |
2016-04-28 |
Genentech Inc |
Anti-FGFR3 antibodies and their use
|
EP2233496A1
(de)
|
2009-03-26 |
2010-09-29 |
Ruhr-Universität Bochum |
Fluoreszenzproteine
|
SG174992A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
CA2752908A1
(en)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
JP5746018B2
(ja)
|
2009-04-16 |
2015-07-08 |
国立大学法人 東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
US8609101B2
(en)
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
CN102459344A
(zh)
|
2009-05-15 |
2012-05-16 |
中外制药株式会社 |
抗axl抗体
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
BRPI1011195B1
(pt)
|
2009-05-20 |
2020-10-13 |
Novimmune S.A |
métodos para produzir uma coleção de ácidos nucleicos
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2436397B1
(de)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
AU2010270894A1
(en)
|
2009-06-24 |
2012-02-09 |
Lpath, Inc. |
Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
CN102471381A
(zh)
|
2009-07-07 |
2012-05-23 |
霍夫曼-拉罗奇有限公司 |
自身免疫性脱髓鞘疾病的诊断和治疗
|
CA2767858C
(en)
|
2009-07-15 |
2019-02-12 |
Portola Pharmaceuticals, Inc. |
Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
|
EP2456890A1
(de)
|
2009-07-20 |
2012-05-30 |
Genentech, Inc. |
Genexpressionsmarker für morbus crohn
|
AR077594A1
(es)
|
2009-07-31 |
2011-09-07 |
Organon Nv |
Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
KR101844859B1
(ko)
|
2009-08-06 |
2018-05-18 |
제넨테크, 인크. |
단백질 정제 시의 바이러스 제거의 개선방법
|
KR101822205B1
(ko)
|
2009-08-11 |
2018-01-25 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
TW201431558A
(zh)
|
2009-08-15 |
2014-08-16 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
US20120282173A1
(en)
|
2009-08-17 |
2012-11-08 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
CN102711809B
(zh)
|
2009-08-17 |
2015-09-30 |
特雷康制药公司 |
使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
|
RU2570554C2
(ru)
|
2009-08-31 |
2015-12-10 |
Роше Гликарт Аг |
Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
|
EP2473524A4
(de)
|
2009-09-01 |
2013-05-22 |
Abbott Lab |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
EP2473531A4
(de)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr-antikörper
|
WO2011032022A1
(en)
|
2009-09-11 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
AU2010297344A1
(en)
|
2009-09-17 |
2012-02-23 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP3187877A1
(de)
|
2009-09-25 |
2017-07-05 |
XOMA Technology Ltd. |
Screening-verfahren
|
EP2483307A1
(de)
|
2009-09-29 |
2012-08-08 |
Fraunhofer USA, Inc. |
Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
|
RU2573896C2
(ru)
|
2009-10-15 |
2016-01-27 |
Дженентек, Инк. |
Химерные факторы роста фибробластов с измененной рецепторной специфичностью
|
KR20140015139A
(ko)
|
2009-10-15 |
2014-02-06 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
GB0918383D0
(en)
|
2009-10-20 |
2009-12-02 |
Cancer Rec Tech Ltd |
Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
|
MX2012004647A
(es)
|
2009-10-22 |
2012-06-19 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso.
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2322149A1
(de)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Ischämie
|
EP2496707B1
(de)
|
2009-11-04 |
2020-02-26 |
Merck Sharp & Dohme Corp. |
Entwickelter antikörper gegen tslp
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
AU2010314981B2
(en)
|
2009-11-05 |
2015-07-02 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
US20120322085A1
(en)
|
2009-11-05 |
2012-12-20 |
Osaka University |
Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
|
AR078986A1
(es)
|
2009-11-12 |
2011-12-14 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas
|
US20120231006A1
(en)
|
2009-11-20 |
2012-09-13 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
JP5856065B2
(ja)
|
2009-11-30 |
2016-02-09 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
RU2559542C2
(ru)
|
2009-12-23 |
2015-08-10 |
Дженентек, Инк. |
Антитела против bv8 и их применение
|
EA201270662A1
(ru)
|
2009-12-23 |
2013-01-30 |
4-Антибоди Аг |
Связывающие элементы для человеческого цитамегаловируса
|
EP2338492A1
(de)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Alzheimer
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
RS59743B1
(sr)
|
2010-01-15 |
2020-02-28 |
Kirin Amgen Inc |
Formulacija antitela protiv il-17ra i terapeutski režimi za lečenje psorijaze
|
HRP20211444T1
(hr)
|
2010-01-29 |
2021-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dll3 antitijelo
|
EP2530109A4
(de)
|
2010-01-29 |
2013-08-28 |
Toray Industries |
Harzfolie auf polymilchsäurebasis
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
MA34059B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Thérapie anti-angiogénique pour le traitement du cancer des ovaires
|
JP5988436B2
(ja)
|
2010-02-23 |
2016-09-07 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
JPWO2011105573A1
(ja)
|
2010-02-26 |
2013-06-20 |
株式会社 未来創薬研究所 |
抗icam3抗体およびその用途
|
WO2011108638A1
(ja)
|
2010-03-04 |
2011-09-09 |
大日本住友製薬株式会社 |
炎症性腸疾患用薬剤
|
ES2722201T3
(es)
|
2010-03-22 |
2019-08-08 |
Hoffmann La Roche |
Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
EP3195880B1
(de)
|
2010-05-14 |
2019-11-27 |
Amgen Inc. |
Hoch-konzentrierte anti-sclerostin antikörperformulierungen
|
WO2011150079A1
(en)
|
2010-05-25 |
2011-12-01 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
EP3299380A1
(de)
|
2010-05-25 |
2018-03-28 |
F. Hoffmann-La Roche AG |
Verfahren zur aufreinigung von polypeptiden
|
US9045544B2
(en)
|
2010-05-28 |
2015-06-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CN103025354A
(zh)
|
2010-06-02 |
2013-04-03 |
大日本住友制药株式会社 |
自身免疫疾病和变应性疾病的治疗药
|
RU2615684C2
(ru)
|
2010-06-14 |
2017-04-06 |
Ликера Биомед Са |
Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии
|
EP4008313A1
(de)
|
2010-06-24 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur stabilisierung von proteinhaltigen formulierungen
|
TW201212938A
(en)
|
2010-06-30 |
2012-04-01 |
Novo Nordisk As |
Antibodies that are capable of specifically binding tissue factor pathway inhibitor
|
EP2591001B1
(de)
|
2010-07-09 |
2021-11-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistischer antikörper zu cd27
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
CN103261225A
(zh)
|
2010-07-23 |
2013-08-21 |
波士顿大学董事会 |
作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
|
CN103298834A
(zh)
|
2010-08-03 |
2013-09-11 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
CN103314296A
(zh)
|
2010-08-10 |
2013-09-18 |
安姆根有限公司 |
用于检测针对靶抗体的中和抗体的双功能体外靶结合测定
|
CA2807664A1
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
WO2012022774A1
(en)
|
2010-08-19 |
2012-02-23 |
Roche Diagnostics Gmbh |
An assay for measurement of antibodies binding to a therapeutic monoclonal antibody
|
CA2809363A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
MA34527B1
(fr)
|
2010-08-27 |
2013-09-02 |
Gilead Biologics Inc |
Anticorps contre la metalloproteinase de matrice 9
|
WO2012030904A2
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
WO2012032043A1
(en)
|
2010-09-07 |
2012-03-15 |
Areva Med Llc |
212 pb imaging
|
WO2012034039A2
(en)
|
2010-09-10 |
2012-03-15 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
US20130263294A1
(en)
|
2010-09-20 |
2013-10-03 |
Bioiberica, S.A. |
Markers for joint displasia, osteoarthritis and conditions secondary thereto
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
EP2623592B1
(de)
|
2010-09-28 |
2019-05-15 |
NB Health Laboratory Co. Ltd. |
Anti-human-ccr7-antikörper, hybridome, medizinische zusammensetzung und antikörper-immobilisierter träger
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
JP5937092B2
(ja)
|
2010-10-19 |
2016-06-22 |
トラスティーズ オブ タフツ カレッジ |
シルクフィブロインベースのマイクロニードルおよびその製造方法
|
EP3214442A1
(de)
|
2010-10-25 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
|
EP2632481A1
(de)
|
2010-10-25 |
2013-09-04 |
Regents Of The University Of Minnesota |
Therapeutische zusammensetzung zur behandlung eines glioblastoms
|
JP6243737B2
(ja)
|
2010-10-27 |
2017-12-06 |
ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク |
E−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
|
MX348025B
(es)
|
2010-11-01 |
2017-05-24 |
Genentech Inc * |
Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
|
WO2012062873A2
(en)
|
2010-11-10 |
2012-05-18 |
Laboratorios Del Dr. Esteve, S.A. |
Highly immunogenic hiv p24 sequences
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CN103347898B
(zh)
|
2011-01-10 |
2017-12-05 |
Ct大西洋有限公司 |
包括与肿瘤相关抗原结合抗体的联合治疗
|
RU2606852C2
(ru)
|
2011-01-11 |
2017-01-10 |
Дзе Гавернинг Каунсил Оф Дзе Юниверсити Оф Торонто |
Способ детекции белков
|
PT2665746T
(pt)
|
2011-01-17 |
2021-02-03 |
Lykera Biomed S A |
Anticorpos contra a proteína s100p para o tratamento e diagnóstico de cancro
|
WO2012100835A1
(en)
|
2011-01-28 |
2012-08-02 |
Laboratorios Del Dr. Esteve, S.A. |
Methods and compositions for the treatment of aids
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
US20140023589A1
(en)
|
2011-02-09 |
2014-01-23 |
Cancer Research Technology Limited |
Frmd4a antagonists and their uses
|
US20120213781A1
(en)
|
2011-02-11 |
2012-08-23 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
BR112013021661A2
(pt)
|
2011-03-02 |
2016-11-22 |
Novo Nordisk As |
objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
EP2683290B1
(de)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Verfahren zum in-vivo-testen von therapeutischen antikörpern
|
AU2012225246B2
(en)
|
2011-03-10 |
2016-01-21 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
BR112013023576A2
(pt)
|
2011-03-15 |
2016-12-06 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
UY33959A
(es)
|
2011-03-16 |
2012-09-28 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
|
EP3235508B1
(de)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
|
EP2500073A1
(de)
|
2011-03-17 |
2012-09-19 |
ChromaCon AG |
Verfahren zur Identifizierung und Reinigung von mehrfach spezifischen Polypeptiden
|
MX2013010737A
(es)
|
2011-03-25 |
2014-03-12 |
Genentech Inc |
Novedosos metodos de purificacion de proteinas.
|
TWI803876B
(zh)
|
2011-03-28 |
2023-06-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
CN109734807A
(zh)
|
2011-03-31 |
2019-05-10 |
豪夫迈·罗氏有限公司 |
施用β7整联蛋白拮抗剂的方法
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
CA2834734A1
(en)
|
2011-04-04 |
2012-10-11 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
EP2694554A1
(de)
|
2011-04-08 |
2014-02-12 |
Gilead Biologics, Inc. |
Verfahren und zusammensetzungen zur normalisierung einer tumorvaskulatur mittels loxl2-hemmung
|
WO2012144208A1
(ja)
|
2011-04-18 |
2012-10-26 |
国立大学法人東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
WO2012145652A1
(en)
|
2011-04-20 |
2012-10-26 |
Trustees Of Tufts College |
Dynamic silk coatings for implantable devices
|
EP2699266B1
(de)
|
2011-04-21 |
2019-06-12 |
Trustees Of Tufts College |
Zusammensetzungen und verfahren zur stabilisierung von wirkstoffen
|
EA032625B1
(ru)
|
2011-05-02 |
2019-06-28 |
Милленниум Фармасьютикалз, Инк. |
КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
WO2012151317A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
US10683362B2
(en)
|
2011-05-06 |
2020-06-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant immunotoxin targeting mesothelin
|
CA2835522C
(en)
|
2011-05-09 |
2019-06-11 |
Duke University |
Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
|
PT2710033T
(pt)
|
2011-05-17 |
2021-03-11 |
Univ Rockefeller |
Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes
|
EP2714735B1
(de)
|
2011-06-03 |
2021-07-21 |
XOMA Technology Ltd. |
Tgf-beta-spezifische antikörper
|
US20140093514A1
(en)
|
2011-06-03 |
2014-04-03 |
University Of Zurich |
Magea3 binding antibodies
|
US20140186363A1
(en)
|
2011-06-03 |
2014-07-03 |
University Of Zurich |
Magea3 binding antibodies
|
CA2838013C
(en)
|
2011-06-09 |
2023-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
EP2721068B1
(de)
|
2011-06-17 |
2018-12-05 |
Novo Nordisk A/S |
Selektive eliminierung erosiver zellen
|
AU2012275133B2
(en)
|
2011-06-30 |
2017-08-17 |
Genzyme Corporation |
Inhibitors of T-cell activation
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
US9150846B2
(en)
|
2011-07-05 |
2015-10-06 |
Bioasis Technologies, Inc. |
P97-antibody conjugates and methods of use
|
WO2013011063A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
WO2013011062A2
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Oscar antagonists
|
WO2013011059A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonist antibodies against oscar
|
WO2013011061A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
EP2734232B1
(de)
|
2011-07-19 |
2017-11-01 |
Philogen S.p.A. |
Sequentielle anti-ctla4 und zielgerichtete il-2 therapie
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
CA2843595C
(en)
|
2011-08-01 |
2022-10-18 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
WO2013022738A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
JP6317670B2
(ja)
|
2011-08-15 |
2018-04-25 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
ブドウ球菌プロテインaに対する抗体に関連した組成物および方法
|
JP2014525412A
(ja)
|
2011-08-17 |
2014-09-29 |
ジェネンテック, インコーポレイテッド |
難治性腫瘍における血管新生の阻害
|
US20150017091A1
(en)
|
2011-08-18 |
2015-01-15 |
Cornell University |
Detection and treatment of metastatic disease
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
EP2749641B1
(de)
|
2011-09-07 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Krebsstammzellenisolierung
|
AU2012305807B2
(en)
|
2011-09-09 |
2015-08-20 |
Department of Medical Sciences (DMSc) |
Dengue-virus serotype neutralizing antibodies
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
ES2656505T3
(es)
|
2011-09-16 |
2018-02-27 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos
|
CN113061993A
(zh)
|
2011-09-30 |
2021-07-02 |
中外制药株式会社 |
离子浓度依赖性结合分子文库
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
EP3418306B1
(de)
|
2011-10-11 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Verbesserter zusammenbau bispezifischer antikörper
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
EP2581388A1
(de)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen sPLA2-V und Gebrauch davon
|
JP6291254B2
(ja)
|
2011-10-28 |
2018-03-14 |
中外製薬株式会社 |
癌幹細胞特異的分子
|
EP2784080B1
(de)
|
2011-10-31 |
2019-12-18 |
Shimadzu Corporation |
Peptidscharnierfreies flexibles antikörperähnliches molekül
|
PL2773438T5
(pl)
|
2011-11-02 |
2022-01-17 |
F.Hoffmann-La Roche Ag |
Chromatografia przeciążenia i elucji
|
CA2854372A1
(en)
|
2011-11-07 |
2013-05-16 |
Universite Laval |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
WO2013070907A1
(en)
|
2011-11-08 |
2013-05-16 |
Tufts University |
A silk-based scaffold platform for engineering tissue constructs
|
BR112014011186A2
(pt)
|
2011-11-09 |
2017-05-09 |
Tufts College |
espumas de fibroína de seda injetáveis e usos das mesmas
|
BR112014011188B1
(pt)
|
2011-11-09 |
2020-05-19 |
Tufts College |
composição injetável para utilização na reparação ou aumento de tecido em indivíduo e dispositivo de entrega compreendendo a referida composição
|
CA2852860C
(en)
|
2011-11-17 |
2020-06-09 |
Matthew David DOROSKI |
Cytotoxic peptides and antibody drug conjugates thereof
|
JP2014533700A
(ja)
|
2011-11-21 |
2014-12-15 |
ジェネンテック, インコーポレイテッド |
抗c−MET抗体の精製
|
MX2014006272A
(es)
|
2011-11-23 |
2014-10-24 |
Igenica Biotherapeutics Inc |
Anticuerpos anti-cd98 y metodos de uso de los mismos.
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
EP2602265A1
(de)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen Anti-sPLA2-X und Verwendungen damit
|
EP2791175A2
(de)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
CA2855840C
(en)
|
2011-12-14 |
2023-08-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
JP6320300B2
(ja)
|
2011-12-19 |
2018-05-09 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
座瘡を治療するための方法
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
EP2794928B1
(de)
|
2011-12-22 |
2019-02-20 |
President and Fellows of Harvard College |
Zusammensetzungen und verfahren zum nachweis von analyten
|
KR20200008022A
(ko)
|
2011-12-22 |
2020-01-22 |
제넨테크, 인크. |
이온 교환 막 크로마토그래피
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
WO2013096948A1
(en)
|
2011-12-23 |
2013-06-27 |
Lydon Nicholas B |
Immunoglobulins and variants directed against pathogenic microbes
|
KR101963230B1
(ko)
|
2011-12-26 |
2019-03-29 |
삼성전자주식회사 |
복수개의 단일 항체를 포함하는 단백질 복합체
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CA2865796A1
(en)
|
2011-12-29 |
2013-07-04 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP3663314A1
(de)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanisierte antikörper mit ultralangem cdr3s
|
WO2013106572A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
RU2644337C2
(ru)
|
2012-01-27 |
2018-02-08 |
Эббви Дойчланд Гмбх Унд Ко. Кг |
Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
|
AR091305A1
(es)
|
2012-01-31 |
2015-01-28 |
Genentech Inc |
ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
|
MX363819B
(es)
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
ES2731441T3
(es)
|
2012-02-29 |
2019-11-15 |
Gilead Biologics Inc |
Anticuerpos dirigidos contra metaloproteinasa 9 de matriz
|
EA201491599A1
(ru)
|
2012-02-29 |
2015-05-29 |
Джилид Байолоджикс, Инк. |
Антитела к матриксной металлопротеиназе 9
|
US20150037358A1
(en)
|
2012-03-09 |
2015-02-05 |
Lankenau Institute For Medical Research |
Composition and Methods for Treating Cancer
|
JP6262196B2
(ja)
|
2012-03-15 |
2018-01-17 |
オメロス コーポレーション |
標的配列の多様化のための組成物および方法
|
JP6200437B2
(ja)
|
2012-03-16 |
2017-09-20 |
ユニバーシティ ヘルス ネットワーク |
Toso活性を調節するための方法および組成物
|
CA2867464A1
(en)
|
2012-03-20 |
2013-09-26 |
Trustees Of Tufts College |
Silk reservoirs for drug delivery
|
EP2641916A1
(de)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
EP3492095A1
(de)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
EP2836236B1
(de)
|
2012-04-13 |
2019-01-02 |
Trustees Of Tufts College |
Verfahren und zusammensetzungen zur herstellung einer seidenmikrokugel
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
EP2841108A4
(de)
|
2012-04-25 |
2015-11-25 |
Tufts College |
Seidenmikrokügelchen sowie verfahren zur oberflächenschmierung
|
CN107964042B
(zh)
|
2012-05-30 |
2022-04-19 |
中外制药株式会社 |
靶组织特异性抗原结合分子
|
EP3556776A1
(de)
|
2012-05-31 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindungsantagonisten und vegf-antagonisten
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
KR102165464B1
(ko)
|
2012-07-19 |
2020-10-14 |
레드우드 바이오사이언스 인코포레이티드 |
Cd22에 대해 특이적인 항체 및 이들의 사용 방법
|
EP2880156B1
(de)
|
2012-07-31 |
2017-08-23 |
biOasis Technologies Inc |
Dephosphorylierte proteine lysosomaler speicherkrankheiten und verwendung davon
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
AU2013302540B2
(en)
|
2012-08-16 |
2018-02-15 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
SG11201501286PA
(en)
|
2012-08-23 |
2015-05-28 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
AU2013320972B2
(en)
|
2012-09-27 |
2018-08-30 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR3 fusion gene and pharmaceutical drug targeting same
|
RU2612878C2
(ru)
|
2012-10-03 |
2017-03-13 |
Филоджен С.П.А. |
Антигены, ассоциированные с воспалительным заболеванием кишечника
|
WO2014055784A1
(en)
|
2012-10-03 |
2014-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
SG11201502548YA
(en)
|
2012-10-05 |
2015-04-29 |
Genentech Inc |
Methods for diagnosing and treating inflammatory bowel disease
|
JP2015533832A
(ja)
|
2012-10-09 |
2015-11-26 |
アイジェニカ バイオセラピューティクス インコーポレイテッド |
抗C16orf54抗体およびその使用方法
|
IL285049B
(en)
|
2012-10-18 |
2022-07-01 |
California Inst Of Techn |
Broad-spectrum neutralizing antibodies against the AIDS virus
|
WO2014066744A2
(en)
|
2012-10-25 |
2014-05-01 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
CA2889208A1
(en)
|
2012-10-30 |
2014-05-08 |
Gilead Sciences, Inc. |
Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
|
KR101911438B1
(ko)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
GB2509260B
(en)
|
2012-11-02 |
2016-05-04 |
True North Therapeutics Inc |
Anti-complement C1s antibodies and uses thereof
|
CN105121421B
(zh)
|
2012-11-05 |
2020-10-02 |
辉瑞公司 |
司普力西欧他汀类似物
|
MX2015005810A
(es)
|
2012-11-07 |
2015-09-23 |
Pfizer |
Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
|
SG11201502876RA
(en)
|
2012-11-08 |
2015-06-29 |
Eleven Biotherapeutics Inc |
Il-6 antagonists and uses thereof
|
EP2920586A4
(de)
|
2012-11-15 |
2017-01-04 |
F. Hoffmann-La Roche SA |
Durch ionenstärke vermittelte ph-gradienten-ionenaustausch-chromatografie
|
EP2922870B1
(de)
|
2012-11-21 |
2019-08-07 |
The Governors of the University of Alberta |
Immunmodulatorische peptide und verfahren zur verwendung davon
|
NZ708033A
(en)
|
2012-12-10 |
2020-03-27 |
Biogen Ma Inc |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
EP2767549A1
(de)
|
2013-02-19 |
2014-08-20 |
Adienne S.A. |
Anti-CD26-Antikörper und Verwendungen davon
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
EP2961412A4
(de)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
Krebstherapie
|
EP2970408B1
(de)
|
2013-03-12 |
2018-01-10 |
Amgen Inc. |
Hochwirksame und selektive inhibitoren von nav1.7
|
EP3744345B1
(de)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antikörperformulierungen
|
ES2774549T3
(es)
|
2013-03-13 |
2020-07-21 |
Bioasis Technologies Inc |
Fragmentos de P97 y usos de los mismos
|
US10081673B2
(en)
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
US10119134B2
(en)
|
2013-03-15 |
2018-11-06 |
Abvitro Llc |
Single cell bar-coding for antibody discovery
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
CA2903546A1
(en)
|
2013-03-15 |
2014-09-25 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
JP6602746B2
(ja)
|
2013-03-15 |
2019-11-06 |
カポン、ダニエル・ジェイ. |
非ペプチジル結合を含むハイブリッド免疫グロブリン
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
ES2695166T3
(es)
|
2013-03-15 |
2019-01-02 |
Intrinsic Lifesciences Llc |
Anticuerpos antihepcidina y usos de los mismos
|
US20140363433A1
(en)
|
2013-03-15 |
2014-12-11 |
Omeros Corporation |
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
|
JP6586016B2
(ja)
|
2013-03-15 |
2019-10-02 |
ノヴォ ノルディスク アー/エス |
組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10233249B2
(en)
|
2013-03-19 |
2019-03-19 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
CN105873950A
(zh)
|
2013-04-09 |
2016-08-17 |
莱克尔生物医学有限公司 |
用于治疗和诊断癌症的抗s100a7抗体
|
EP2983710B1
(de)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Behandlungsverfahren für neuromyelitis optica
|
CA2911514A1
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
US20160115231A1
(en)
|
2013-05-21 |
2016-04-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Treatment of mast cell related pathologies
|
WO2014192915A1
(ja)
|
2013-05-30 |
2014-12-04 |
国立大学法人 千葉大学 |
抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
CA3173775A1
(en)
|
2013-06-10 |
2014-12-18 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
EP3008201B1
(de)
|
2013-06-12 |
2019-08-07 |
The General Hospital Corporation |
Verfahren für multiplex-nachweis von zielmolekülen und verwendungen dafür
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
RU2016101716A
(ru)
|
2013-06-24 |
2017-07-27 |
Чугаи Сейяку Кабусики Кайся |
Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
SG11201510316UA
(en)
|
2013-07-09 |
2016-01-28 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
EP3021869B1
(de)
|
2013-07-16 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und tigit-inhibitoren
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
CN105658666B
(zh)
|
2013-08-01 |
2021-07-27 |
鲁汶大学 |
抗garp蛋白及其用途
|
EP3027210A1
(de)
|
2013-08-02 |
2016-06-08 |
Aduro Biotech Holdings, Europe B.V. |
Kombination von cd27-agonisten und immun-checkpoint-hemmung zur immunstimulation
|
CN107318267B
(zh)
|
2013-08-12 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
用于治疗补体相关的病症的组合物和方法
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
CA2922439A1
(en)
|
2013-08-29 |
2015-03-05 |
University Of Copenhagen |
Anti-adam12 antibodies for the treatment of cancer
|
CA2921639A1
(en)
|
2013-09-05 |
2015-03-12 |
Aduro Biotech Holdings, Europe B.V. |
Cd70-binding peptides and method, process and use relating thereto
|
US20150093800A1
(en)
|
2013-09-05 |
2015-04-02 |
Genentech, Inc. |
Method for chromatography reuse
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
AU2014317990A1
(en)
|
2013-09-06 |
2016-02-25 |
Theranos Ip Company, Llc |
Systems and methods for detecting infectious diseases
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
NZ756750A
(en)
|
2013-09-13 |
2022-05-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
PL3044323T3
(pl)
|
2013-09-13 |
2022-06-27 |
F.Hoffmann-La Roche Ag |
Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
|
GB201317207D0
(en)
|
2013-09-27 |
2013-11-13 |
Univ Glasgow |
Materials and methods for modulating disc1 turnover
|
BR112016006197B1
(pt)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Método para produzir um anticorpo biespecífico de polipeptídeos
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
EP3940065A1
(de)
|
2013-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung eines antigenbindenden moleküls unter verwendung von modifizierten helferphagen
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
CA3120508A1
(en)
|
2013-10-28 |
2015-05-07 |
Dots Technology Corp. |
Allergen detection
|
US20160297892A1
(en)
|
2013-11-07 |
2016-10-13 |
Novo Nordisk A/S |
Novel Methods and Antibodies for Treating Coagulapathy
|
CN113278076A
(zh)
|
2013-11-11 |
2021-08-20 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
CN105722523B
(zh)
|
2013-11-15 |
2022-06-14 |
豪夫迈·罗氏有限公司 |
使用环保洗涤剂的病毒灭活方法
|
JP6555687B2
(ja)
|
2013-11-20 |
2019-08-07 |
国立大学法人北海道大学 |
免疫制御剤
|
JP6879739B2
(ja)
|
2013-11-25 |
2021-06-02 |
フェイムウェイヴ リミテッド |
癌治療のための抗ceacam1および抗pd抗体を含む組成物
|
EP2876114A1
(de)
|
2013-11-25 |
2015-05-27 |
Consejo Superior De Investigaciones Científicas |
Antikörper gegen CCR9 und Anwendungen davon
|
WO2015081073A2
(en)
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
WO2015081085A2
(en)
|
2013-11-27 |
2015-06-04 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
CA2932607A1
(en)
|
2013-12-03 |
2015-06-11 |
President And Fellows Of Harvard College |
Methods and reagents for the assessment of gestational diabetes
|
AU2014358191B2
(en)
|
2013-12-04 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量(hmw)タウ種およびその用途
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
DK3083694T3
(da)
|
2013-12-20 |
2024-01-29 |
Intervet Int Bv |
Caniniserede, murine anti-canin-pd-1-antistoffer
|
MX2016006529A
(es)
|
2013-12-20 |
2016-08-03 |
Genentech Inc |
Anticuerpos dobles especificos.
|
EP3581179A1
(de)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
|
CN106062005A
(zh)
|
2013-12-30 |
2016-10-26 |
医药生命融合研究团 |
抗krs单克隆抗体及其用途
|
EP2896400A1
(de)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
MX2016009555A
(es)
|
2014-01-24 |
2016-12-08 |
Ngm Biopharmaceuticals Inc |
Proteinas de union y metodos para utilizarlas.
|
MY180257A
(en)
|
2014-01-27 |
2020-11-26 |
Pfizer |
Bifunctional cytotoxic agents
|
AU2015210612B2
(en)
|
2014-02-03 |
2020-04-09 |
Bioasis Technologies Inc. |
P97 fusion proteins
|
EP3105252B1
(de)
|
2014-02-12 |
2019-07-24 |
Michael Uhlin |
Bispezifische antikörper zur verwendung in der stammzelltransplantation
|
WO2015126729A1
(en)
|
2014-02-19 |
2015-08-27 |
Bioasis Technologies, Inc. |
P97-ids fusion proteins
|
KR20160125466A
(ko)
|
2014-02-27 |
2016-10-31 |
길리애드 사이언시즈, 인코포레이티드 |
매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법
|
CA2941693A1
(en)
|
2014-03-07 |
2015-09-11 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
SI3701971T1
(sl)
|
2014-03-14 |
2023-01-31 |
Biomolecular Holdings LLC, |
Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
WO2015143343A2
(en)
|
2014-03-21 |
2015-09-24 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
MX2016012282A
(es)
|
2014-03-27 |
2017-01-06 |
Genentech Inc |
Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
US10703798B2
(en)
|
2014-03-31 |
2020-07-07 |
Debiopharm International Sa |
Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
|
PT3126391T
(pt)
|
2014-03-31 |
2019-11-27 |
Univ Hospital Of North Norway |
Anticorpos contra hpa-1a
|
US9995746B2
(en)
|
2014-04-02 |
2018-06-12 |
The United States Of America, As Represented By The Secretary Of The Army |
Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
|
US20170045528A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
US20170044257A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
PL3137502T3
(pl)
|
2014-04-27 |
2021-03-08 |
Famewave Ltd. |
Humanizowane przeciwciała przeciwko CEACAM1
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
EP3140392B1
(de)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Herstellung von heteromultimeren proteinen mittels säugerzellen
|
PT3148581T
(pt)
|
2014-05-30 |
2020-01-06 |
Henlix Biotech Co Ltd |
Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
|
LT3151859T
(lt)
|
2014-06-09 |
2021-03-25 |
Ultragenyx Pharmaceutical Inc. |
Veiksminga ir efektyvi serumo fosfatų kontrolė optimaliam kaulų formavimosi užtikrinimui
|
CN106456772A
(zh)
|
2014-06-11 |
2017-02-22 |
吉利德科学公司 |
用于治疗心血管疾病的方法
|
RS59353B1
(sr)
|
2014-06-12 |
2019-10-31 |
Ra Pharmaceuticals Inc |
Modulacija aktivnosti komplementa
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
US20170240631A1
(en)
|
2014-08-08 |
2017-08-24 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
HUE059131T2
(hu)
|
2014-08-11 |
2022-10-28 |
Acerta Pharma Bv |
BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
MA40475A
(fr)
|
2014-08-19 |
2017-06-28 |
Fayadat Dilman Laurence |
Anticorps anti-tigit
|
WO2016026143A1
(en)
|
2014-08-22 |
2016-02-25 |
Huiru Wang |
Saccharide-based biomarkers and therapeutics
|
ES2727656T3
(es)
|
2014-09-15 |
2019-10-17 |
Abvitro Llc |
Secuenciación de alto rendimiento de banco de nucleótidos
|
MX2017003121A
(es)
|
2014-09-15 |
2017-08-02 |
Genentech Inc |
Formulaciones de anticuerpos.
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
US10759860B2
(en)
|
2014-09-16 |
2020-09-01 |
Synermore Biologics Co., Ltd. |
Anti-EGFR antibody and uses of same
|
WO2016049036A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
HUE046181T2
(hu)
|
2014-11-07 |
2020-02-28 |
Sesen Bio Inc |
Javított ellenanyagok IL-6 ellen
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
JP2018500882A
(ja)
|
2014-11-10 |
2018-01-18 |
ジェネンテック, インコーポレイテッド |
腎症の動物モデルおよびそれを治療するための薬剤
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
PT3218005T
(pt)
|
2014-11-12 |
2023-04-11 |
Seagen Inc |
Compostos que interagem com glicano e métodos de uso
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
BR112017010268B1
(pt)
|
2014-11-19 |
2024-01-16 |
P & M Venge Ab |
Agente de ligação, composição de diagnóstico, kit de diagnóstico, método de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral, métodos para descartar uma infecção bacteriana ou viral em um indivíduo, métodos para considerar uma infecção bacteriana ou viral em um indivíduo, método para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo, método para descartar uma doença infecciosa, método para identificação do tipo de infecção e dispositivo para o diagnóstico de infecções bacterianas
|
EP3221445B1
(de)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
|
EP3224280A1
(de)
|
2014-11-26 |
2017-10-04 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab zur behandlung von fistelbildendem morbus crohn
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
JP2017538412A
(ja)
|
2014-12-11 |
2017-12-28 |
インバイオモーション エセ.エレ. |
ヒトc−mafに対する結合メンバー
|
WO2016097420A1
(en)
|
2014-12-19 |
2016-06-23 |
Universite De Nantes |
Anti il-34 antibodies
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
JP2018502084A
(ja)
|
2014-12-23 |
2018-01-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ベータ細胞への変換と組み合わせられたアルファ細胞の再生
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
EP3250230B9
(de)
|
2015-01-28 |
2022-02-23 |
RA Pharmaceuticals, Inc. |
Modulatoren der komplementaktivität
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
WO2016125017A1
(en)
|
2015-02-03 |
2016-08-11 |
Universite Catholique De Louvain |
Anti-garp protein and uses thereof
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
EP3816179A3
(de)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-region-variante, mit einer modifizierten fcrn-bindungsdomäne
|
EP4134430A1
(de)
|
2015-02-06 |
2023-02-15 |
National University of Singapore |
Verfahren zur verbesserung der wirksamkeit therapeutischer immunzellen
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
CN107405401B
(zh)
|
2015-02-26 |
2022-02-01 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
JP6865689B2
(ja)
|
2015-03-06 |
2021-04-28 |
ジェネンテック, インコーポレイテッド |
超精製DsbA及びDsbC、ならびにそれらの作製及び使用方法
|
US20180057588A1
(en)
|
2015-03-16 |
2018-03-01 |
Aarhus Universitet |
Antibodies Towards an Extracellular Region of NBCn1
|
CA2979895A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
AU2016235662B2
(en)
|
2015-03-20 |
2020-07-30 |
Aarhus Universitet |
Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
|
AU2016238551B2
(en)
|
2015-03-20 |
2020-01-02 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the CTI pharmacophore
|
WO2016157195A1
(en)
|
2015-04-01 |
2016-10-06 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP3954710A3
(de)
|
2015-04-02 |
2022-07-20 |
Intervet International B.V. |
Antikörper gegen interleukin-4-rezeptor-alpha des hundes
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
RU2754041C2
(ru)
|
2015-04-03 |
2021-08-25 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/мнс, и виды их использования
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
CN107921090A
(zh)
|
2015-04-06 |
2018-04-17 |
苏伯多曼有限责任公司 |
含有从头结合结构域的多肽及其用途
|
US10729767B2
(en)
|
2015-04-06 |
2020-08-04 |
Bioverativ Usa Inc. |
Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage
|
CA2981851A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
EP3081575A1
(de)
|
2015-04-12 |
2016-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-plasmodium-parasiten-antikörper
|
AU2016248817A1
(en)
|
2015-04-17 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
EP4238994A3
(de)
|
2015-05-11 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
WO2016184987A1
(en)
|
2015-05-19 |
2016-11-24 |
Yaya Diagnostics Gmbh |
Means and methods for the enrichment of nucleic acids
|
EP3718569B1
(de)
|
2015-05-22 |
2023-05-03 |
Translational Drug Development, LLC |
Benzamid- und aktivverbindungszusammensetzungen und verwendungsmethoden
|
US20180134788A1
(en)
|
2015-05-26 |
2018-05-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
AU2016267691B2
(en)
|
2015-05-28 |
2022-06-16 |
Genentech, Inc. |
Cell-based assay for detecting anti-CD3 homodimers
|
MX2017014735A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metilacion de promotor pd-l1 en cancer.
|
MX2017015619A
(es)
|
2015-06-01 |
2018-08-15 |
Medigene Immunotherapies Gmbh |
Anticuerpos especificos de receptor de celulas t.
|
EA201792661A1
(ru)
|
2015-06-01 |
2018-05-31 |
Медиджин Иммьюнотерапиз Гмбх |
Способ получения антител против т-клеточного рецептора
|
WO2016193299A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
EP3307777A4
(de)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Neuartige anti-pd-l1-antikörper
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
CN116063499A
(zh)
|
2015-06-12 |
2023-05-05 |
艾利妥 |
抗cd33抗体及其使用方法
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3310810A1
(de)
|
2015-06-16 |
2018-04-25 |
Merck Patent GmbH |
Kombinationsbehandlungen mit pd-l1-antagonisten
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
KR101750411B1
(ko)
|
2015-07-10 |
2017-06-27 |
한국생명공학연구원 |
엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
|
US10287338B2
(en)
|
2015-07-10 |
2019-05-14 |
Miran NERSISSIAN |
Factor VIII protein compositions and methods of treating of hemophilia A
|
WO2017023863A1
(en)
|
2015-07-31 |
2017-02-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
MX2018001465A
(es)
|
2015-08-05 |
2019-01-31 |
Acticor Biotech |
Nuevos anticuerpos anti-gpvi humana y sus usos.
|
WO2017021023A1
(en)
|
2015-08-06 |
2017-02-09 |
Yaya Diagnostics Gmbh |
Means and methods for the detection of targets
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
CN115960235A
(zh)
|
2015-08-28 |
2023-04-14 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
CA2995639A1
(en)
|
2015-09-02 |
2017-03-09 |
Immutep S.A.S. |
Anti-lag-3 antibodies
|
EP4223784A3
(de)
|
2015-09-02 |
2023-10-04 |
The Regents of the University of Colorado, a body corporate |
Zusammensetzungen und verfahren zur modulation der t-zell-vermittelten immunantwort
|
CN108137691B
(zh)
|
2015-09-02 |
2021-10-19 |
耶路撒冷希伯来大学伊萨姆研究发展有限公司 |
特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
EP3350216A1
(de)
|
2015-09-15 |
2018-07-25 |
Amgen Inc. |
Tetravalente bispezifische und tetraspezifische antigenbindende proteine und verwendungen davon
|
EP3350212A1
(de)
|
2015-09-18 |
2018-07-25 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
T-zell-rezeptoren (tcr) und verwendungen davon zur diagnose und behandlung von diabetes
|
CN113372443A
(zh)
|
2015-09-18 |
2021-09-10 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
MA42924A
(fr)
|
2015-09-23 |
2018-08-01 |
Hoffmann La Roche |
Variants optimisés d'anticorps anti-vegf
|
CA2999888C
(en)
|
2015-09-24 |
2024-04-09 |
Abvitro Llc |
Affinity-oligonucleotide conjugates and uses thereof
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
WO2017050955A1
(en)
|
2015-09-24 |
2017-03-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agents capable of inhibiting the binding between leptin and vegf165
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
CN113774495A
(zh)
|
2015-09-25 |
2021-12-10 |
阿布维特罗有限责任公司 |
用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法
|
KR20180054824A
(ko)
|
2015-09-29 |
2018-05-24 |
셀진 코포레이션 |
Pd-1 결합 단백질 및 이의 사용 방법
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
EP3356415B1
(de)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr-inhibitoren
|
WO2017058780A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
JP2018537956A
(ja)
|
2015-10-06 |
2018-12-27 |
アレクトル エルエルシー |
抗trem2抗体及びその使用方法
|
EP3359572A2
(de)
|
2015-10-06 |
2018-08-15 |
H. Hoffnabb-La Roche Ag |
Verfahren zur behandlung von multipler sklerose
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
EP3365027B1
(de)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
CA3003458A1
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
EP3922649B1
(de)
|
2015-10-30 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Anti-htra1-antikörper und verfahren zur verwendung davon
|
JP6902185B2
(ja)
|
2015-11-03 |
2021-07-14 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Cd200阻害剤及びその使用方法
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
WO2017106061A1
(en)
|
2015-12-14 |
2017-06-22 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
EA202091898A1
(ru)
|
2015-12-15 |
2021-06-22 |
Джилид Сайэнс, Инк. |
Антитела, нейтрализующие вирус иммунодефицита человека
|
JP7000322B2
(ja)
|
2015-12-16 |
2022-02-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗lag3抗体および抗原結合性フラグメント
|
AU2016370210A1
(en)
|
2015-12-16 |
2018-06-21 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
US10588953B2
(en)
|
2015-12-18 |
2020-03-17 |
Agilvax, Inc. |
Compositions and methods related to xCT peptides
|
EP3395366B1
(de)
|
2015-12-21 |
2023-11-22 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Wirkstoffdesignverfahren, erhaltener wirkstoff und anwendung davon
|
JP6697562B2
(ja)
|
2015-12-23 |
2020-05-20 |
メディジーン イミュノテラピーズ ゲーエムベーハー |
樹状細胞組成物
|
EP3398965A4
(de)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
AU2017205185B2
(en)
|
2016-01-07 |
2022-03-31 |
The Schepens Eye Research Institute, Inc. |
Therapeutics for ocular immunoinflammatory diseases
|
US10472422B2
(en)
|
2016-01-08 |
2019-11-12 |
Abgenomics International Inc. |
Tetravalent anti-PSGL-1 antibodies and uses thereof
|
PL3402503T3
(pl)
|
2016-01-13 |
2021-04-19 |
Acerta Pharma B.V. |
Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
|
EP3851457A1
(de)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
KR20180104036A
(ko)
|
2016-01-22 |
2018-09-19 |
머크 샤프 앤드 돔 코포레이션 |
항-응고 인자 xi 항체
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
EP3408397B1
(de)
|
2016-01-27 |
2020-07-15 |
Just-Evotec Biologics, Inc. |
Hybrider promoter und verwendungen davon
|
US10822415B2
(en)
|
2016-01-28 |
2020-11-03 |
Inserm (Institut National De La Santéet De La Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
US10918737B2
(en)
|
2016-01-28 |
2021-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
EP3411371A1
(de)
|
2016-02-01 |
2018-12-12 |
Pfizer Inc |
Tubulysinanaloga und verfahren zu deren herstellung
|
WO2017139975A1
(en)
|
2016-02-19 |
2017-08-24 |
Huiru Wang |
Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
IL296874A
(en)
|
2016-03-01 |
2022-11-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Antibodies specific for the human poliovirus receptor
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
US11340219B2
(en)
|
2016-03-17 |
2022-05-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-pY1235-MET immunological binding reagent
|
CN111363041B
(zh)
|
2016-03-23 |
2022-02-22 |
苏州创胜医药集团有限公司 |
新型抗-pd-l1抗体
|
EP3433278A4
(de)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
|
SG10202009423QA
(en)
|
2016-03-28 |
2020-11-27 |
Incyte Corp |
Pyrrolotriazine compounds as tam inhibitors
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
AU2017240233B2
(en)
|
2016-03-31 |
2022-07-14 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
CN109563158B
(zh)
|
2016-04-04 |
2022-08-09 |
比奥贝拉蒂美国公司 |
抗补体因子bb抗体以及其用途
|
US20200330459A1
(en)
|
2016-04-06 |
2020-10-22 |
Inserm (Institut National De La Santé Et La Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
US10954287B2
(en)
|
2016-04-15 |
2021-03-23 |
Ra Pharmaceuticals, Inc. |
Ras binding peptides and methods of use
|
US20190125826A1
(en)
|
2016-04-22 |
2019-05-02 |
Inserm (Institut National De La Santé Et De La Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
US11376269B2
(en)
|
2016-05-06 |
2022-07-05 |
Inserm |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
US11142548B2
(en)
|
2016-05-10 |
2021-10-12 |
Sorbonne Universite |
Agents that activate CD47 and their use in the treatment of inflammation
|
CN109312408B
(zh)
|
2016-05-17 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
用于诊断和供免疫疗法中使用的基质基因签名
|
WO2017202962A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
CN116425879A
(zh)
|
2016-06-14 |
2023-07-14 |
默沙东有限责任公司 |
抗-凝血因子xi抗体
|
CN109563124A
(zh)
|
2016-06-17 |
2019-04-02 |
豪夫迈·罗氏有限公司 |
多特异性抗体的纯化
|
DK3264087T3
(da)
|
2016-06-27 |
2020-07-20 |
Chimera Biotec Gmbh |
Fremgangsmåde og indretning til kvantificering af målmolekyler
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487880A1
(de)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5(grp78)-antikörper und verwendungen davon
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
US11447542B2
(en)
|
2016-08-05 |
2022-09-20 |
Medimmune, Llc |
Anti-O2 antibodies and uses thereof
|
JP7286536B2
(ja)
|
2016-08-15 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
|
PL3733712T3
(pl)
|
2016-08-15 |
2023-10-16 |
Novartis Ag |
Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
EP3509637A4
(de)
|
2016-09-06 |
2020-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur verwendung eines bispezifischen antikörpers mit erkennung des gerinnungsfaktors ix und/oder aktivierten gerinnungsfaktors ix und gerinnungsfaktors x und/oder aktivierten gerinnungsfaktors x
|
EP3510046A4
(de)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
Antikörper gegen oxidationsspezifische epitope
|
WO2018049418A1
(en)
|
2016-09-12 |
2018-03-15 |
IsoPlexis Corporation |
System and methods for multiplexed analysis of cellular and other immunotherapeutics
|
US20190248907A1
(en)
|
2016-09-14 |
2019-08-15 |
Merck Patent Gmbh |
Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition
|
AU2017328633A1
(en)
|
2016-09-15 |
2019-03-21 |
Novimmune Sa |
Bispecific antibody display on phage surface
|
BR112019005129A2
(pt)
|
2016-09-16 |
2019-06-04 |
Shanghai Henlius Biotech Inc |
anticorpos anti-pd-1
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
EP3515943A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
|
CA3035875A1
(en)
|
2016-09-20 |
2018-03-29 |
Aarhus Universitet |
Compounds for treatment of lipoprotein metabolism disorders
|
EP3515950A4
(de)
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
Neuartige anti-pcsk9-antikörper
|
WO2018055031A1
(en)
|
2016-09-21 |
2018-03-29 |
Aarhus Universitet |
Acid-base transport inhibitors
|
EP3516071B1
(de)
|
2016-09-22 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von lungenkrebs
|
BR112019005748A2
(pt)
|
2016-09-24 |
2019-06-18 |
Abvitro Llc |
afinidade-conjugados de oligonucleotídeo e usos destes
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
KR20190057113A
(ko)
|
2016-09-28 |
2019-05-27 |
조마 (유에스) 엘엘씨 |
인터루킨-2에 결합하는 항체 및 그 용도
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
US20180106800A1
(en)
|
2016-10-03 |
2018-04-19 |
Abbott Laboratories |
Methods of assessing uch-l1 status in patient samples
|
US10941195B2
(en)
|
2016-10-04 |
2021-03-09 |
Fairbanks Pharmaceuticals, Inc. |
Anti-follistatin-like 3 antibodies and treatment of diabetes
|
EP3522923A1
(de)
|
2016-10-06 |
2019-08-14 |
Pfizer Inc |
Dosierschema für avelumab zur behandlung von krebs
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
CA3039686A1
(en)
|
2016-10-19 |
2018-04-26 |
Medimmune, Llc |
Anti-o1 antibodies and uses thereof
|
BR112019008345A8
(pt)
|
2016-10-25 |
2023-03-07 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais ligados à isoforma transmembrana cd160
|
US20190263926A1
(en)
|
2016-10-28 |
2019-08-29 |
Astute Medical, Inc. |
Use of Antibodies to TIMP-2 for the Improvement of Renal Function
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
US11617815B2
(en)
|
2016-10-31 |
2023-04-04 |
Sofregen Medical, Inc. |
Compositions comprising silk fibroin particles and uses thereof
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
JP7348066B2
(ja)
|
2016-11-11 |
2023-09-20 |
アイソプレキシス コーポレイション |
単一細胞のゲノム、トランスクリプトームおよびプロテオームの同時解析のための組成物および方法
|
EP3541408A4
(de)
|
2016-11-15 |
2020-06-24 |
The Schepens Eye Research Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von aberrierender angiogene
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
US11135266B2
(en)
|
2016-11-21 |
2021-10-05 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations and uses thereof
|
IL300095A
(en)
|
2016-11-23 |
2023-03-01 |
Translational Drug Dev Llc |
Compositions of benzamide and an agonist for the cancer necrosis factor receptor superfamily and uses thereof
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
US20200081010A1
(en)
|
2016-12-02 |
2020-03-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
KR20190093196A
(ko)
|
2016-12-07 |
2019-08-08 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절인자
|
CA3045857A1
(en)
|
2016-12-22 |
2018-06-28 |
Universita Degli Studi Magna Graecia Catanzaro |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3565589A1
(de)
|
2017-01-04 |
2019-11-13 |
Research Institute at Nationwide Children's Hospital |
Dnabii-impfstoffe und antikörper mit erhöhter aktivität
|
EP3565586A1
(de)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Erweiterung von tumorinfiltrierenden lymphozyten mit kaliumkanalagonisten und therapeutische verwendungen davon
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP4046989A1
(de)
|
2017-01-09 |
2022-08-24 |
Shuttle Pharmaceuticals, Inc. |
Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
EP3573995A1
(de)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Calicheamicin-derivate und antikörper-wirkstoff-konjugate davon
|
KR102633644B1
(ko)
|
2017-02-03 |
2024-02-05 |
액티코어 바이오테크 |
항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
|
JP7341060B2
(ja)
|
2017-02-10 |
2023-09-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
|
CN116715775A
(zh)
|
2017-02-10 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CR20190468A
(es)
|
2017-03-14 |
2019-12-17 |
Bioverativ Usa Inc |
Métodos para tratar enfermedades y trastornos mediados por completo
|
WO2018170178A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
WO2018166495A1
(en)
|
2017-03-15 |
2018-09-20 |
Tsinghua University |
Novel anti-trkb antibodies
|
CN111010875B
(zh)
|
2017-03-15 |
2024-04-05 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
SG11201908650PA
(en)
|
2017-03-22 |
2019-10-30 |
Genentech Inc |
Optimized antibody compositions for treatment of ocular disorders
|
SG10202107829YA
(en)
|
2017-03-22 |
2021-08-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
EP3600410A1
(de)
|
2017-03-30 |
2020-02-05 |
Merck Patent GmbH |
Kombination aus einem anti-pd-l1-antikörper und einem dna-pk-inhibitor zur behandlung von krebs
|
EP3600308A1
(de)
|
2017-03-30 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren zur behandlung von mitochondrialen genetischen erkrankungen
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
EP3606518A4
(de)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
CN110944665B
(zh)
|
2017-04-14 |
2024-04-19 |
埃克塞里艾克西斯公司 |
用于预防或治疗肺癌的amhrii结合化合物
|
BR112019021472A8
(pt)
|
2017-04-14 |
2023-05-02 |
Inst Curie |
Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
|
EP3610268A1
(de)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Verfahren zur unterstützung bei der hyperakuten diagnose und bestimmung von traumatischen hirnverletzungen in einem menschlichen patienten mit frühbiomarkern
|
TW201902927A
(zh)
|
2017-04-21 |
2019-01-16 |
美商梅利特公司 |
糖尿病相關應用之方法及抗體
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
KR102663596B1
(ko)
|
2017-04-26 |
2024-05-10 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CN110832070A
(zh)
|
2017-05-10 |
2020-02-21 |
艾欧凡斯生物治疗公司 |
液体肿瘤来源肿瘤浸润淋巴细胞的扩增及其治疗用途
|
GB201707561D0
(en)
|
2017-05-11 |
2017-06-28 |
Argenx Bvba |
GARP-TGF-beta antibodies
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
CN111148849A
(zh)
|
2017-05-26 |
2020-05-12 |
阿布维托有限责任公司 |
高通量多核苷酸文库测序和转录组分析
|
AU2018275236A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
EP3638218A4
(de)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
US20210403573A1
(en)
|
2017-06-22 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
EP3645567A1
(de)
|
2017-06-27 |
2020-05-06 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifizierung und behandlung von resistenz gegen ctla4-antagonisten bei leukämie
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
CN111050808A
(zh)
|
2017-07-06 |
2020-04-21 |
纪念斯隆-凯特林癌症中心 |
用于抗dota/抗肿瘤抗原双特异性抗体预靶向放射免疫治疗的dota-半抗原组合物
|
WO2019014044A1
(en)
|
2017-07-12 |
2019-01-17 |
The Johns Hopkins University |
ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和***病毒感染的抗体和方法
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
WO2019023525A1
(en)
|
2017-07-28 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
|
BR112019023789A2
(pt)
|
2017-08-03 |
2020-07-28 |
Alector Llc |
anticorpos anti-cd33 e métodos de uso dos mesmos
|
PT3601358T
(pt)
|
2017-08-03 |
2023-08-30 |
Alector Llc |
Anticorpos anti-trem2 e métodos de uso dos mesmos
|
US11085929B2
(en)
|
2017-08-31 |
2021-08-10 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
|
KR20200090151A
(ko)
|
2017-09-20 |
2020-07-28 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
신규한 항-hla-a2 항체 및 이의 용도
|
WO2019057742A1
(en)
|
2017-09-20 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA
|
EP3688007A1
(de)
|
2017-09-27 |
2020-08-05 |
The University of York |
Biokonjugation von polypeptiden
|
CA3071236A1
(en)
|
2017-09-29 |
2019-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
CN117430699A
(zh)
|
2017-09-30 |
2024-01-23 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
EP3691656A1
(de)
|
2017-10-06 |
2020-08-12 |
Camp4 Therapeutics Corporation |
Verfahren und zusammensetzungen zur behandlung von harnstoffzyklusstörungen, insbesondere von otc-mangel
|
EP3694552A1
(de)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap-antikörper und verwendungen davon
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
US11897969B2
(en)
|
2017-10-26 |
2024-02-13 |
The Regents Of The University Of California |
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
|
GB201717966D0
(en)
|
2017-10-31 |
2017-12-13 |
Xenikos Bv |
Immunotoxins, formulations thereof and their use in medicine
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
JP7416700B2
(ja)
|
2017-11-14 |
2024-01-17 |
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド |
増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのrunx1阻害の方法
|
EA202091198A1
(ru)
|
2017-11-14 |
2020-09-09 |
Эрселлкс, Инк. |
Полипептиды, содержащие домен d, и их применение
|
SG11202004426SA
(en)
|
2017-11-17 |
2020-06-29 |
Merck Sharp & Dohme |
Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
|
CN111356471A
(zh)
|
2017-11-20 |
2020-06-30 |
济世发展生物药业有限公司 |
包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
|
EP3714041A1
(de)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
WO2019113506A1
(en)
|
2017-12-07 |
2019-06-13 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
BR112019028254A2
(pt)
|
2017-12-09 |
2020-07-14 |
Abbott Laboratories |
métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
|
AU2018378084A1
(en)
|
2017-12-09 |
2020-05-14 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
SG11202005557TA
(en)
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
CN111741973A
(zh)
|
2017-12-19 |
2020-10-02 |
洛克菲勒大学 |
具有改进的效应子功能的人IgG Fc结构域变体
|
CN111699198B
(zh)
|
2017-12-28 |
2023-09-05 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
EP3732203A4
(de)
|
2017-12-28 |
2021-12-15 |
Nanjing Legend Biotech Co., Ltd. |
Antikörper und varianten davon gegen pd-l1
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
EP3732489A1
(de)
|
2017-12-29 |
2020-11-04 |
Abbott Laboratories |
Neuartige biomarker und verfahren zur diagnose und bewertung von traumatischer hirnverletzung
|
EP3735590A1
(de)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von resistentem melanom
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
JP2021510594A
(ja)
|
2018-01-25 |
2021-04-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
臓器の虚血再灌流傷害を予防する方法における使用のためのil−33のアンタゴニスト
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
AU2019218128A1
(en)
|
2018-02-09 |
2020-09-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
US11685781B2
(en)
|
2018-02-15 |
2023-06-27 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
JP7384811B2
(ja)
|
2018-02-16 |
2023-11-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白斑を処置するための方法及び組成物
|
US20200384030A1
(en)
|
2018-02-21 |
2020-12-10 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CR20200441A
(es)
|
2018-02-27 |
2021-03-15 |
Incyte Corp |
Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
KR20200138720A
(ko)
|
2018-03-30 |
2020-12-10 |
난징 레전드 바이오테크 씨오., 엘티디. |
Lag-3에 대한 단일-도메인 항체 및 이의 용도
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
EP3774883A1
(de)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antikörper und fragmente davon, die hepatitis-b-virus-protein x binden
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
WO2019197678A1
(en)
|
2018-04-13 |
2019-10-17 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
TWI811335B
(zh)
|
2018-04-13 |
2023-08-11 |
美商建南德克公司 |
穩定抗cd79b免疫結合物調配物
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019213619A1
(en)
|
2018-05-04 |
2019-11-07 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
AU2019264229A1
(en)
|
2018-05-04 |
2020-12-03 |
Merck Patent Gmbh |
Combined inhibition of PD-1/PD-L1, TGFβ and DNA-PK for the treatment of cancer
|
US20210386829A1
(en)
|
2018-05-04 |
2021-12-16 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
EP3790900A1
(de)
|
2018-05-09 |
2021-03-17 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Für menschliches nectin4 spezifische antikörper
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
EP3797121A1
(de)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc |
Cd3-spezifische antikörper und verwendungen davon
|
CN113286634A
(zh)
|
2018-05-23 |
2021-08-20 |
辉瑞公司 |
对gucy2c特异性的抗体及其用途
|
JP7360401B2
(ja)
|
2018-05-31 |
2023-10-12 |
グリコネックス インコーポレイテッド |
バイアンテナ型ルイスbおよびルイスy抗原に結合する治療抗体
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
JP2021525806A
(ja)
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
EP3801767A1
(de)
|
2018-06-08 |
2021-04-14 |
Alector LLC |
Anti-siglec-7-antikörper und verfahren zur verwendung davon
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
CN112955464A
(zh)
|
2018-06-20 |
2021-06-11 |
因赛特公司 |
抗pd-1抗体及其用途
|
US11241438B2
(en)
|
2018-06-29 |
2022-02-08 |
Incyte Corporation |
Formulations of an AXL/MER inhibitor
|
EP3817819A1
(de)
|
2018-07-03 |
2021-05-12 |
Gilead Sciences, Inc. |
Antikörper gegen hiv gp120 und verwendungsverfahren
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
BR112019022666A2
(pt)
|
2018-07-13 |
2020-09-01 |
Alector Llc |
anticorpos antissortilina e métodos de uso dos mesmos
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
EA202190183A1
(ru)
|
2018-07-27 |
2021-05-18 |
Алектор Ллс |
Антитела к siglec-5 и способы их применения
|
PL3830120T3
(pl)
|
2018-07-31 |
2023-10-09 |
Pieris Pharmaceuticals Gmbh |
NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1
|
EP3833446A2
(de)
|
2018-08-10 |
2021-06-16 |
Sangamo Therapeutics France |
Neue car-konstrukte mit tnfr2-domänen
|
CN113166241A
(zh)
|
2018-08-16 |
2021-07-23 |
约翰霍普金斯大学 |
人类znt8抗体
|
CN112955221A
(zh)
|
2018-08-27 |
2021-06-11 |
皮里斯制药有限公司 |
包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
AU2019336426A1
(en)
|
2018-09-04 |
2021-04-29 |
Nanjing Umab-Biopharma Co., Ltd. |
Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
EP3853251A1
(de)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von krebserkrankungen mit resistenz gegen immun-checkpoint-therapie
|
WO2020061429A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
EP3626265A1
(de)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-cd45rc-antikörper und verwendungen davon
|
WO2020064702A1
(en)
|
2018-09-25 |
2020-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
CA3114295A1
(en)
|
2018-09-28 |
2020-04-02 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
US20210340278A1
(en)
|
2018-10-04 |
2021-11-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
|
CA3114925A1
(en)
|
2018-10-05 |
2020-04-09 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for enzymatic disruption of bacterial biofilms
|
US20210347898A1
(en)
|
2018-10-09 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
EP3863722A2
(de)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap-antikörper und verwendungen davon
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
US20210395751A1
(en)
|
2018-10-31 |
2021-12-23 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
JP2022512863A
(ja)
|
2018-11-02 |
2022-02-07 |
アネクソン,インコーポレーテッド |
脳損傷を治療するための組成物及び方法
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
GB201818618D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against ambra-1
|
GB201818622D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against loricrin
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020128927A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
SG11202107257UA
(en)
|
2019-01-03 |
2021-07-29 |
Inst Nat Sante Rech Med |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
EP3908678A1
(de)
|
2019-01-10 |
2021-11-17 |
Iovance Biotherapeutics, Inc. |
System und verfahren zur überwachung der klonalität und persistenz von adoptiven zelltherapien
|
US20220112283A1
(en)
|
2019-01-13 |
2022-04-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human nectin-2
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
WO2020159836A1
(en)
|
2019-01-28 |
2020-08-06 |
Maple Biotech Llc |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
CN113711036A
(zh)
|
2019-01-30 |
2021-11-26 |
真和制药有限公司 |
抗gal3抗体及其用途
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
CR20210471A
(es)
|
2019-02-15 |
2021-12-08 |
Integral Molecular Inc |
Anticuerpos claudina 6 y usos de los mismos
|
AU2020223376A1
(en)
|
2019-02-15 |
2021-07-22 |
Just - Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
CA3130051A1
(en)
|
2019-02-18 |
2020-08-27 |
Nb Health Laboratory Co., Ltd. |
Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
|
US20220153864A1
(en)
|
2019-02-26 |
2022-05-19 |
Pieris Pharmaceuticals Gmbh |
Novel Fusion Proteins Specific for CD137 and GPC3
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
AU2020231308A1
(en)
|
2019-03-01 |
2021-08-19 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
KR20210136050A
(ko)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
WO2020178313A1
(en)
|
2019-03-05 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New biomarkers and biotargets in renal cell carcinoma
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020186235A1
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
US20220152148A1
(en)
|
2019-03-18 |
2022-05-19 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
EP3942023A1
(de)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
EP3942026A1
(de)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
Neue inhibitoren der lrrk2/pp1-interaktion
|
WO2020194317A1
(en)
|
2019-03-28 |
2020-10-01 |
Yeda Research And Development Co. Ltd. |
Method of treating lipid-related disorders
|
EP3946417A1
(de)
|
2019-03-29 |
2022-02-09 |
Pieris Pharmaceuticals GmbH |
Inhalierte verabreichung von lipocalin-muteinen
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
SG11202110043TA
(en)
|
2019-04-01 |
2021-10-28 |
Genentech Inc |
Compositions and methods for stabilizing protein-containing formulations
|
WO2020206033A1
(en)
|
2019-04-02 |
2020-10-08 |
Kenjockety Biotechnology, Inc. |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
EP3947737A2
(de)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
|
JP2022527345A
(ja)
|
2019-04-03 |
2022-06-01 |
オレガ・バイオテック |
Pd1阻害剤及びil-17b阻害剤に基づく複合療法
|
AU2020253455A1
(en)
|
2019-04-03 |
2021-11-04 |
Genzyme Corporation |
Anti-alpha beta TCR binding polypeptides with reduced fragmentation
|
JP2022527372A
(ja)
|
2019-04-08 |
2022-06-01 |
バイオジェン・エムエイ・インコーポレイテッド |
抗インテグリン抗体及びそれらの使用
|
JP2022528804A
(ja)
|
2019-04-18 |
2022-06-15 |
ジェネンテック, インコーポレイテッド |
抗体力価試験
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
GB201906297D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Biomarkers for disease progression in squamous cell carcinoma
|
EP3962924A1
(de)
|
2019-05-03 |
2022-03-09 |
Genentech, Inc. |
Verfahren zur verminderung der enzymatischen hydrolyseaktivitätsrate in einer aus einer reinigungsplattform erhaltenen zusammensetzung
|
GB201906302D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Methods of determining the margin of a tumour
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
BR112021022514A2
(pt)
|
2019-05-10 |
2022-04-19 |
Takeda Pharmaceuticals Co |
Conjugados de anticorpo e fármaco
|
EP3972997A1
(de)
|
2019-05-20 |
2022-03-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neuartige anti-cd25-antikörper
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
EP3972993A1
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variante cd58-domänen und deren verwendungen
|
WO2020236795A2
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
WO2020237491A1
(en)
|
2019-05-28 |
2020-12-03 |
Shanghaitech University |
Composition and methods to treat ectodermal dysplasia 2, clouston type
|
EP3976643A2
(de)
|
2019-05-30 |
2022-04-06 |
Amgen Inc. |
Engineering des gelenkbereichs zur steuerung der dimerisierung von antikörpern
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
CA3142635A1
(en)
|
2019-06-04 |
2020-12-10 |
Biotheus Inc. |
Anti-ceacam5 monoclonal antibody and preparation method thereof and use thereof
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
JPWO2020246617A1
(de)
|
2019-06-07 |
2020-12-10 |
|
|
MX2021015791A
(es)
|
2019-06-28 |
2022-04-01 |
Amgen Inc |
Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
|
MX2022000137A
(es)
|
2019-07-08 |
2022-05-19 |
Res Inst Nationwide Childrens Hospital |
Composiciones de anticuerpos para la ruptura de biopelículas.
|
CN114174337A
(zh)
|
2019-07-15 |
2022-03-11 |
英特维特国际股份有限公司 |
针对犬ctla-4的犬源化抗体
|
WO2021009263A1
(en)
|
2019-07-16 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
US20220275105A1
(en)
|
2019-08-02 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
GB201911210D0
(en)
|
2019-08-06 |
2019-09-18 |
Amlo Biosciences Ltd |
Clinical management of oropharyngeal squamous cell carcinoma
|
EP4014050A1
(de)
|
2019-08-12 |
2022-06-22 |
Voyager Therapeutics, Inc. |
Hochempfindlicher immunoassay zur detektion von frataxin in biofluiden
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
CN114423454A
(zh)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体的给药
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
CA3155930A1
(en)
|
2019-09-27 |
2021-04-01 |
Starkage Therapeutics |
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
|
US10975169B1
(en)
|
2019-09-27 |
2021-04-13 |
Memorial Sloan Kettering Cancer Center |
Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
EP4037714A1
(de)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur modulation von makrophagen-polarisation
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
GB201914399D0
(en)
|
2019-10-04 |
2019-11-20 |
Univ Newcastle |
Biomarkers for assessing explant organ viability
|
JP2022550434A
(ja)
|
2019-10-04 |
2022-12-01 |
ティーエーイー ライフ サイエンシーズ |
Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11738174B2
(en)
|
2019-10-15 |
2023-08-29 |
Sofregen Medical, Inc. |
Delivery devices for delivering and methods of delivering compositions
|
EP3808766A1
(de)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
US20240166763A1
(en)
|
2019-11-04 |
2024-05-23 |
Pieris Pharmaceuticals Gmbh |
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
|
US20220403022A1
(en)
|
2019-11-05 |
2022-12-22 |
Merck Patent Gmbh |
Anti-TIGIT Antibodies and Uses Thereof
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
JP2023503429A
(ja)
|
2019-11-22 |
2023-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤
|
KR20220110537A
(ko)
|
2019-12-05 |
2022-08-08 |
알렉터 엘엘씨 |
항-trem2 항체 사용 방법
|
WO2021116277A1
(en)
|
2019-12-10 |
2021-06-17 |
Institut Pasteur |
New antibody blocking human fcgriiia and fcgriiib
|
GB201918103D0
(en)
|
2019-12-10 |
2020-01-22 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
AU2020403021A1
(en)
|
2019-12-12 |
2022-06-23 |
Alector Llc |
Methods of use of anti-CD33 antibodies
|
CA3164623A1
(en)
|
2019-12-17 |
2021-06-24 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
US20210230294A1
(en)
|
2020-01-03 |
2021-07-29 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
WO2021138467A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Anti-cd73 antibodies and uses thereof
|
AU2020417813A1
(en)
|
2020-01-03 |
2022-08-25 |
Incyte Corporation |
Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
JP2023511595A
(ja)
|
2020-01-27 |
2023-03-20 |
ジェネンテック, インコーポレイテッド |
抗tigitアンタゴニスト抗体を用いたがんを処置するための方法
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009355A
(es)
|
2020-01-29 |
2022-09-02 |
Kenjockety Biotechnology Inc |
Anticuerpo anti-mdr1 y uso del mismo.
|
CA3167693A1
(en)
|
2020-02-21 |
2021-08-26 |
Jean-Claude Twizere |
Depletion of ext1 expression and/or activity improves cellular production of biological entities
|
KR20220157400A
(ko)
|
2020-02-24 |
2022-11-29 |
오블리크 세러퓨틱스 에이비 |
Kras 에피토프 및 항체
|
WO2021173565A1
(en)
|
2020-02-24 |
2021-09-02 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
US11920136B2
(en)
|
2020-02-28 |
2024-03-05 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
JP2023514957A
(ja)
|
2020-02-28 |
2023-04-12 |
オレガ・バイオテック |
Ctla4阻害剤及びil-17b阻害剤に基づく複合療法
|
CN115697343A
(zh)
|
2020-03-06 |
2023-02-03 |
因赛特公司 |
包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
|
JP2023517345A
(ja)
|
2020-03-13 |
2023-04-25 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン-33抗体及びその使用
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
EP4132568A1
(de)
|
2020-04-06 |
2023-02-15 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Antikörper gegen nkp46 und konstrukte davon zur behandlung von krebs und infektionen
|
US20230132275A1
(en)
|
2020-04-08 |
2023-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
US20230149360A1
(en)
|
2020-04-21 |
2023-05-18 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
|
JP2023525664A
(ja)
|
2020-04-21 |
2023-06-19 |
ユニヴェルシテ カソリーク デ ルーヴァン |
がんの処置のためのアルファ-2アドレナリン作動性受容体アゴニスト
|
US20230159939A1
(en)
|
2020-04-22 |
2023-05-25 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids
|
KR20230004520A
(ko)
|
2020-04-27 |
2023-01-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
지단백(a)에 대한 이소형-비의존성 항체
|
CA3176894A1
(en)
|
2020-04-30 |
2021-11-04 |
Marco DE BRUYN |
Anti-cd103 antibodies
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
GB202007312D0
(en)
|
2020-05-18 |
2020-07-01 |
Synthetic Vac Ltd |
Mimotope peptides of the spike protein from the sars-cov-2 virus
|
GB202007404D0
(en)
|
2020-05-19 |
2020-07-01 |
Nasser Syed Muhammad Tahir |
Treatment for viral respiratory infections
|
EP4157881A1
(de)
|
2020-05-27 |
2023-04-05 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antikörper, die spezifisch den nervenwachstumsfaktor erkennen, und deren verwendungen
|
CA3176246A1
(en)
|
2020-06-02 |
2021-12-09 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
AU2021283080A1
(en)
|
2020-06-04 |
2022-12-15 |
Kenjockety Biotechnology, Inc. |
ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
AU2021284240A1
(en)
|
2020-06-04 |
2022-12-08 |
Kenjockety Biotechnology, Inc. |
Anti-ABCG2 antibodies and uses thereof
|
US20230227568A1
(en)
|
2020-06-05 |
2023-07-20 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
WO2022007955A1
(zh)
|
2020-07-09 |
2022-01-13 |
北京凯因科技股份有限公司 |
结合乙型肝炎病毒表面抗原的抗体及其应用
|
US11524998B2
(en)
|
2020-07-16 |
2022-12-13 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
JP2023535610A
(ja)
|
2020-07-28 |
2023-08-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを予防及び処置するための方法及び組成物
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
IL300528A
(en)
|
2020-08-07 |
2023-04-01 |
Fortis Therapeutics Inc |
Immune conjugates targeting cd46 and methods of using them
|
US20230322955A1
(en)
|
2020-08-20 |
2023-10-12 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
US20230287082A1
(en)
|
2020-09-01 |
2023-09-14 |
Merck Patent Gmbh |
Nkp30 binders
|
JP2023539883A
(ja)
|
2020-09-02 |
2023-09-20 |
ケンジョッケティ バイオテクノロジー,インク. |
抗abcc1抗体及びその使用
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
US20230366884A1
(en)
|
2020-09-18 |
2023-11-16 |
Pieris Pharmaceuticals Gmbh |
Biomarker methods and uses
|
CN116323674A
(zh)
|
2020-09-21 |
2023-06-23 |
基因泰克公司 |
多特异性抗体的纯化
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
EP4225330A1
(de)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
MX2023004088A
(es)
|
2020-10-07 |
2023-04-27 |
Amgen Inc |
Seleccion racional de bloques de construccion para el ensamblaje de anticuerpos multiespecificos.
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
EP4229081A1
(de)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
|
US20230414700A1
(en)
|
2020-10-15 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
|
WO2022082217A1
(en)
|
2020-10-16 |
2022-04-21 |
Eureka Therapeutics, Inc. |
Compositions for preventing or treating viral and other microbial infections
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
CN116507395A
(zh)
|
2020-10-30 |
2023-07-28 |
基因泰克公司 |
用于获得具有降低的水解酶活性率的药物组合物的纯化平台
|
WO2022098762A1
(en)
|
2020-11-03 |
2022-05-12 |
IsoPlexis Corporation |
Methods and devices for mulitplexed proteomic and genetic analysis and on-device preparation of cdna
|
WO2022096547A1
(en)
|
2020-11-05 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
EP4240491A1
(de)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19-bindende moleküle und verwendungen davon
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
PE20231947A1
(es)
|
2020-11-09 |
2023-12-05 |
Takeda Pharmaceuticals Co |
Conjugados de anticuerpo y farmaco
|
AU2021379598A1
(en)
|
2020-11-10 |
2023-06-08 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
CA3195799A1
(en)
|
2020-11-11 |
2022-05-19 |
Stephen R. Martin |
Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
|
US20240010747A1
(en)
|
2020-11-13 |
2024-01-11 |
Kenjockety Biotechnology, Inc. |
Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
KR20230118108A
(ko)
|
2020-11-20 |
2023-08-10 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-cd25 항체
|
US20240002521A1
(en)
|
2020-11-20 |
2024-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd25 antibodies
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
GB202019522D0
(en)
|
2020-12-10 |
2021-01-27 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
IL303638A
(en)
|
2020-12-16 |
2023-08-01 |
Voyager Therapeutics Inc |
tau binding compounds
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
CA3207066A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
TW202242085A
(zh)
|
2020-12-31 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
供自動生產腫瘤浸潤淋巴球的裝置和方法
|
EP4271482A2
(de)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
CA3207206A1
(en)
|
2021-02-01 |
2022-08-04 |
Lingfeng LIU |
Targeted protein degradation system and use thereof
|
JP2024507124A
(ja)
|
2021-02-11 |
2024-02-16 |
ネクチン セラピューティクス リミテッド |
Cd112rに対する抗体およびその使用
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
WO2022178253A1
(en)
|
2021-02-19 |
2022-08-25 |
IsoPlexis Corporation |
Methods and devices for spatially resolved analysis of proteomic and genetic information
|
EP4301776A1
(de)
|
2021-03-04 |
2024-01-10 |
Centre National de la Recherche Scientifique (CNRS) |
Verwendung eines periostin-antikörpers zur behandlung von entzündungen, fibrose und lungenerkrankungen
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
AU2022238526A1
(en)
|
2021-03-15 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
EP4308118A1
(de)
|
2021-03-17 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und zusammensetzungen zur melanombehandlung
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
EP4313099A2
(de)
|
2021-03-23 |
2024-02-07 |
Pieris Pharmaceuticals GmbH |
Her2/4-1bb bispezifische fusionsproteine zur behandlung von krebs
|
JP2024512567A
(ja)
|
2021-03-23 |
2024-03-19 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
T細胞リンパ腫の診断および治療方法
|
TW202305118A
(zh)
|
2021-03-23 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途
|
WO2022200478A1
(en)
|
2021-03-24 |
2022-09-29 |
Pieris Pharmaceuticals Gmbh |
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
|
EP4314253A2
(de)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
|
JP2024515564A
(ja)
|
2021-04-08 |
2024-04-10 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
結合組織増殖因子(ctgf)に特異的な新規リポカリンムテイン
|
EP4320153A1
(de)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von anaplastischem grosszelligem lymphom
|
WO2022214664A1
(en)
|
2021-04-09 |
2022-10-13 |
Philogen S.P.A. |
Improved interferon-gamma mutant
|
WO2022219152A1
(en)
|
2021-04-16 |
2022-10-20 |
Oblique Therapeutics Ab |
Kras antibodies
|
EP4326871A1
(de)
|
2021-04-19 |
2024-02-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von splice-switching-oligonukleotiden zum exon-skipping-vermittelten knockdown von pim2
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
CN117651714A
(zh)
|
2021-04-20 |
2024-03-05 |
美国安进公司 |
多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
|
WO2022223824A1
(en)
|
2021-04-23 |
2022-10-27 |
Philogen S.P.A |
Anti-fibroblast activation protein antibodies
|
EP4326903A1
(de)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Verfahren und zusammensetzungen zur behandlung von krankheiten im zusammenhang mit zellalterungsansammlung
|
EP4340850A1
(de)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1-geneditierte tumorinfiltrierende lymphozyten und verwendungen davon in der immuntherapie
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
EP4342913A1
(de)
|
2021-05-19 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
Chimäres antigenrezeptormolekül zur spezifischen erkennung von baff-r und anwendung eines chimären antigenrezeptormoleküls
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
EP4356129A1
(de)
|
2021-06-14 |
2024-04-24 |
Abbott Laboratories |
Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
|
EP4357365A1
(de)
|
2021-06-16 |
2024-04-24 |
Shanghai Sinobay Biotechnology Co., Ltd. |
Antikörper gegen axl-protein und antigenbindendes fragment davon sowie herstellungsverfahren dafür und anwendung davon
|
EP4359437A2
(de)
|
2021-06-22 |
2024-05-01 |
Merck Patent GmbH |
Vhh-basierte nkp30-bindemittel
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
CN117915951A
(zh)
|
2021-07-02 |
2024-04-19 |
默克专利股份有限公司 |
抗protac抗体及复合物
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
EP4370555A1
(de)
|
2021-07-13 |
2024-05-22 |
TrueBinding, Inc. |
Verfahren zur verhinderung von proteinaggregation
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023287707A1
(en)
|
2021-07-15 |
2023-01-19 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
KR20240038768A
(ko)
|
2021-07-30 |
2024-03-25 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키메라 단백질 및 면역치료 방법
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023017149A1
(en)
|
2021-08-13 |
2023-02-16 |
Oblique Therapeutics Ab |
Thioredoxin 1 antibodies
|
WO2023028186A1
(en)
|
2021-08-27 |
2023-03-02 |
Abbott Laboratories |
Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
IL311333A
(en)
|
2021-09-09 |
2024-05-01 |
Iovance Biotherapeutics Inc |
Processes for the production of TIL products using a strong PD-1 TALEN
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2023067348A1
(en)
|
2021-10-21 |
2023-04-27 |
Biosirius Ltd |
Treatment for virally-induced pneumonia
|
WO2023072958A1
(en)
|
2021-10-25 |
2023-05-04 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids and the products thereof
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
AR127728A1
(es)
|
2021-11-19 |
2024-02-21 |
Pieris Pharmaceuticals Gmbh |
Nueva proteína de fusión específica para ox40 y pd-l1
|
US20230272055A1
(en)
|
2021-12-08 |
2023-08-31 |
Incyte Corporation |
Anti-mutant calreticulin (calr) antibodies and uses thereof
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
CA3238353A1
(en)
|
2021-12-13 |
2023-06-22 |
William Robert ARATHOON |
Anti-abcb1 antibodies
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023114884A2
(en)
|
2021-12-15 |
2023-06-22 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023118497A1
(en)
|
2021-12-22 |
2023-06-29 |
Pieris Pharmaceuticals Gmbh |
Novel il-18 variants
|
WO2023122796A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Parallel antibody engineering compositions and methods
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023156683A1
(en)
|
2022-02-21 |
2023-08-24 |
Acticor Biotech |
Treatment of cardiovascular diseases using anti-human gpvi antibodies
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
GB202202569D0
(en)
|
2022-02-24 |
2022-04-13 |
Amlo Biosciences Ltd |
Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
|
WO2023170207A1
(en)
|
2022-03-09 |
2023-09-14 |
Alderaan Biotechnology |
Anti-cd160 transmembrane isoform antibodies
|
WO2023180523A1
(en)
|
2022-03-24 |
2023-09-28 |
Pieris Pharmaceuticals Gmbh |
Process for purifying fusion proteins
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4257609A1
(de)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023237431A1
(en)
|
2022-06-07 |
2023-12-14 |
Esocap Ag |
Drug delivery system comprising an agent effective in the treatment or prevention of an esophageal disease for the application to esophageal mucous membranes
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
EP4311557A1
(de)
|
2022-07-26 |
2024-01-31 |
Oncomatryx Biopharma, S.L. |
Auf fap abzielende antikörper-arzneimittelkonjugate
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024088921A1
(en)
|
2022-10-24 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Predicting response to il-6 antagonists
|
WO2024092240A1
(en)
|
2022-10-28 |
2024-05-02 |
Chinook Therapeutics, Inc. |
Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
|
WO2024097328A1
(en)
|
2022-11-03 |
2024-05-10 |
Incyte Corporation |
Combination therapies comprising an anti-gitr antibody for treating cancers
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100663A1
(en)
|
2022-11-10 |
2024-05-16 |
Famewave Ltd. |
Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
|